CZ20033444A3 - Azaindoles - Google Patents
Azaindoles Download PDFInfo
- Publication number
- CZ20033444A3 CZ20033444A3 CZ20033444A CZ20033444A CZ20033444A3 CZ 20033444 A3 CZ20033444 A3 CZ 20033444A3 CZ 20033444 A CZ20033444 A CZ 20033444A CZ 20033444 A CZ20033444 A CZ 20033444A CZ 20033444 A3 CZ20033444 A3 CZ 20033444A3
- Authority
- CZ
- Czechia
- Prior art keywords
- pyrrolo
- indol
- methyl
- pyridin
- methoxy
- Prior art date
Links
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 title description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 742
- 150000003839 salts Chemical class 0.000 claims abstract description 97
- 239000012453 solvate Substances 0.000 claims abstract description 64
- -1 cyclic acetal Chemical class 0.000 claims description 334
- 125000000217 alkyl group Chemical group 0.000 claims description 172
- 229910052739 hydrogen Inorganic materials 0.000 claims description 152
- 238000000034 method Methods 0.000 claims description 151
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 138
- 125000001072 heteroaryl group Chemical group 0.000 claims description 122
- 229910005965 SO 2 Inorganic materials 0.000 claims description 120
- 125000003118 aryl group Chemical group 0.000 claims description 118
- 239000001257 hydrogen Substances 0.000 claims description 86
- 229940002612 prodrug Drugs 0.000 claims description 84
- 239000000651 prodrug Substances 0.000 claims description 84
- 150000001204 N-oxides Chemical class 0.000 claims description 78
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 77
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 76
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 76
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 66
- 239000000203 mixture Substances 0.000 claims description 59
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 55
- 229910052736 halogen Inorganic materials 0.000 claims description 50
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 47
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 47
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 46
- 125000003342 alkenyl group Chemical group 0.000 claims description 42
- 125000005843 halogen group Chemical group 0.000 claims description 36
- 239000002253 acid Substances 0.000 claims description 35
- 230000002378 acidificating effect Effects 0.000 claims description 35
- 125000004432 carbon atom Chemical group C* 0.000 claims description 31
- 150000002367 halogens Chemical group 0.000 claims description 30
- 125000003545 alkoxy group Chemical group 0.000 claims description 29
- 229910052799 carbon Inorganic materials 0.000 claims description 29
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 28
- 125000001041 indolyl group Chemical group 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 235000019260 propionic acid Nutrition 0.000 claims description 21
- NCODGTKJFCNVAH-UHFFFAOYSA-N 1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxylic acid Chemical compound C12=CC(C(O)=O)=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 NCODGTKJFCNVAH-UHFFFAOYSA-N 0.000 claims description 20
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims description 20
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 20
- VAJOSPMTARTPKN-UHFFFAOYSA-N 2-[5-methoxy-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]-1-morpholin-4-ylethanone Chemical compound C1=C(C=2NC3=NC=CN=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCOCC1 VAJOSPMTARTPKN-UHFFFAOYSA-N 0.000 claims description 19
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 19
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000006414 CCl Chemical group ClC* 0.000 claims description 17
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 17
- 150000002431 hydrogen Chemical group 0.000 claims description 17
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 16
- 230000003197 catalytic effect Effects 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- CVDGAVDNVQNYQT-UHFFFAOYSA-N 1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxylic acid Chemical compound C12=CC(C(O)=O)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 CVDGAVDNVQNYQT-UHFFFAOYSA-N 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 14
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 13
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 12
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- RVHRALDRJAGLNN-UHFFFAOYSA-N 1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-6-carboxylic acid Chemical compound C12=CC=C(C(O)=O)C=C2N(C)C=C1C1=CC2=CC=CN=C2N1 RVHRALDRJAGLNN-UHFFFAOYSA-N 0.000 claims description 11
- MIJMZVTYIXYSDK-UHFFFAOYSA-N 6-(5-methoxy-1-methylindol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=N1 MIJMZVTYIXYSDK-UHFFFAOYSA-N 0.000 claims description 11
- 101100298295 Drosophila melanogaster flfl gene Proteins 0.000 claims description 11
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 11
- 125000004076 pyridyl group Chemical group 0.000 claims description 11
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 11
- RPOHBQMVRIVWKP-UHFFFAOYSA-N 1-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxypropan-2-ol Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OCC(O)C)=CC2=C1 RPOHBQMVRIVWKP-UHFFFAOYSA-N 0.000 claims description 10
- LIZDNKRMTCXMAV-UHFFFAOYSA-N 3-[4-(3,5-dimethyl-1,2-oxazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-2-yl]-1-methylindole-5-carboxylic acid Chemical compound CC1=NOC(C)=C1C1=CC=NC2=C1C=C(C=1C3=CC(=CC=C3N(C)C=1)C(O)=O)N2 LIZDNKRMTCXMAV-UHFFFAOYSA-N 0.000 claims description 10
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 10
- 108090000461 Aurora Kinase A Proteins 0.000 claims description 10
- 102100032311 Aurora kinase A Human genes 0.000 claims description 10
- 229910014033 C-OH Inorganic materials 0.000 claims description 10
- 229910014570 C—OH Inorganic materials 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 claims description 10
- 229940080818 propionamide Drugs 0.000 claims description 10
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 claims description 9
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 9
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 claims description 9
- QBUASRVBPRBVRJ-UHFFFAOYSA-N 1-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxycyclobutane-1-carboxamide Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=1OC1(C(N)=O)CCC1 QBUASRVBPRBVRJ-UHFFFAOYSA-N 0.000 claims description 8
- VZLHVQTYCPRPHS-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1 VZLHVQTYCPRPHS-UHFFFAOYSA-N 0.000 claims description 8
- FTJGHPGHUSLQAK-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carbonitrile Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1C#N FTJGHPGHUSLQAK-UHFFFAOYSA-N 0.000 claims description 8
- CIDALPHOFCAXQR-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carbonitrile Chemical compound C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=C1C#N CIDALPHOFCAXQR-UHFFFAOYSA-N 0.000 claims description 8
- CYGVUQDIFRECJA-UHFFFAOYSA-N 4-[2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]-3,5-dimethyl-1,2-oxazole Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2C=1C(C)=NOC=1C CYGVUQDIFRECJA-UHFFFAOYSA-N 0.000 claims description 8
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 8
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 8
- ZUHZMIKTWRJJLA-UHFFFAOYSA-N 1-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]ethanone Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)C)=CC2=C1 ZUHZMIKTWRJJLA-UHFFFAOYSA-N 0.000 claims description 7
- AZEKOCYKHUJNKS-UHFFFAOYSA-N 1-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxycyclobutane-1-carboxylic acid Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=1OC1(C(O)=O)CCC1 AZEKOCYKHUJNKS-UHFFFAOYSA-N 0.000 claims description 7
- AVNBDKGXTGVKOZ-UHFFFAOYSA-N 1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-ol Chemical compound C12=CC(O)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 AVNBDKGXTGVKOZ-UHFFFAOYSA-N 0.000 claims description 7
- UVGZNKUGQAZSFE-UHFFFAOYSA-N 1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C12=CC(C(N)=O)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 UVGZNKUGQAZSFE-UHFFFAOYSA-N 0.000 claims description 7
- HVPYZVWMSSBUNJ-UHFFFAOYSA-N 2-(1-ethyl-5-methoxyindol-3-yl)-n-(1-hydroxy-2-methylpropan-2-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C12=CC(OC)=CC=C2N(CC)C=C1C1=CC2=C(C(=O)NC(C)(C)CO)C=CN=C2N1 HVPYZVWMSSBUNJ-UHFFFAOYSA-N 0.000 claims description 7
- GZRCWJUTTURNJO-UHFFFAOYSA-N 2-(5,6-dimethoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C=3C=4C=C(C(=CC=4N(C)C=3)OC)OC)=CC2=C1 GZRCWJUTTURNJO-UHFFFAOYSA-N 0.000 claims description 7
- FKDHQBOTZUDZEJ-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-4-pyridin-3-yl-1h-pyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2C1=CC=CN=C1 FKDHQBOTZUDZEJ-UHFFFAOYSA-N 0.000 claims description 7
- MCTZIYPXXHBZEW-UHFFFAOYSA-N 2-[1-methyl-5-(2-methyltetrazol-5-yl)indol-3-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound CN1N=NC(C=2C=C3C(C=4NC5=NC=CC=C5C=4)=CN(C)C3=CC=2)=N1 MCTZIYPXXHBZEW-UHFFFAOYSA-N 0.000 claims description 7
- SMCLLQQYFYBQQL-UHFFFAOYSA-N 2-[5-methoxy-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]ethanol Chemical compound C1=CN=C2NC(C3=CN(CCO)C4=CC=C(C=C43)OC)=CC2=N1 SMCLLQQYFYBQQL-UHFFFAOYSA-N 0.000 claims description 7
- JHUWLGXCOIMHHQ-UHFFFAOYSA-N 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indole-5-carboxylic acid Chemical compound C1=CN=C2NC(C3=CNC4=CC=C(C=C43)C(=O)O)=CC2=C1 JHUWLGXCOIMHHQ-UHFFFAOYSA-N 0.000 claims description 7
- HIWPOKJDACYAFJ-UHFFFAOYSA-N 3-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-2-yl)-1-methylindole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2C(C=3NC=4N=CC=C(C=4C=3)OC)=CN(C)C2=C1 HIWPOKJDACYAFJ-UHFFFAOYSA-N 0.000 claims description 7
- BZGCYSXNPHENAB-UHFFFAOYSA-N 3-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]propanoic acid Chemical compound C12=CC(CCC(O)=O)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 BZGCYSXNPHENAB-UHFFFAOYSA-N 0.000 claims description 7
- VEKQEFMQDFQZSJ-UHFFFAOYSA-N 3-[3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]propan-1-ol Chemical compound C12=CC=CC=C2N(CCCO)C=C1C1=CC2=NC=CN=C2N1 VEKQEFMQDFQZSJ-UHFFFAOYSA-N 0.000 claims description 7
- BSONOAQXFAIGPB-UHFFFAOYSA-N 3-[5-methoxy-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]propan-1-ol Chemical compound C1=CN=C2NC(C3=CN(CCCO)C4=CC=C(C=C43)OC)=CC2=N1 BSONOAQXFAIGPB-UHFFFAOYSA-N 0.000 claims description 7
- YHKXZXWIOPNPDS-UHFFFAOYSA-N 3-[[1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carbonyl]amino]propanoic acid Chemical compound C12=CC(C(=O)NCCC(O)=O)=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 YHKXZXWIOPNPDS-UHFFFAOYSA-N 0.000 claims description 7
- AZZIWMRQTCNYEQ-UHFFFAOYSA-N 4-chloro-2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=C1Cl AZZIWMRQTCNYEQ-UHFFFAOYSA-N 0.000 claims description 7
- QFSGJFOPYOPYRB-UHFFFAOYSA-N 4-methoxy-2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=C1OC QFSGJFOPYOPYRB-UHFFFAOYSA-N 0.000 claims description 7
- IKISMFQWQNPZGJ-UHFFFAOYSA-N 6-(1h-indol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC(C=3C4=CC=CC=C4NC=3)=CC2=N1 IKISMFQWQNPZGJ-UHFFFAOYSA-N 0.000 claims description 7
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 7
- RKSSWPMEKJQARM-UHFFFAOYSA-N [3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]methanol Chemical compound C12=CC=CC=C2N(CO)C=C1C1=CC2=NC=CN=C2N1 RKSSWPMEKJQARM-UHFFFAOYSA-N 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- JOZNPCHRNZOWDU-UHFFFAOYSA-N n-(2-hydroxyethyl)-1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NCCO)=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 JOZNPCHRNZOWDU-UHFFFAOYSA-N 0.000 claims description 7
- CJEABCXNJXZHHG-UHFFFAOYSA-N n-(2-methoxyethyl)-1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)NCCOC)=CC2=N1 CJEABCXNJXZHHG-UHFFFAOYSA-N 0.000 claims description 7
- IFEWOIRZUBHZIP-UHFFFAOYSA-N n-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]acetamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)NC(=O)C)=CC2=C1 IFEWOIRZUBHZIP-UHFFFAOYSA-N 0.000 claims description 7
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
- 125000003107 substituted aryl group Chemical group 0.000 claims description 7
- MUQFTYHVZUPXES-CYBMUJFWSA-N (2r)-3-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxypropane-1,2-diol Chemical compound C12=CC(OC[C@H](O)CO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 MUQFTYHVZUPXES-CYBMUJFWSA-N 0.000 claims description 6
- SAYAZSFRHPSZLZ-CYBMUJFWSA-N (2r)-3-[6-methoxy-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxypropane-1,2-diol Chemical compound C1=CN=C2NC(C3=CN(C)C=4C=C(C(=CC=43)OC[C@H](O)CO)OC)=CC2=C1 SAYAZSFRHPSZLZ-CYBMUJFWSA-N 0.000 claims description 6
- KYWSGFFFDGCSES-UHFFFAOYSA-N 1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-5-ol Chemical compound C12=CC(O)=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 KYWSGFFFDGCSES-UHFFFAOYSA-N 0.000 claims description 6
- NGRLVNLOYHSCOT-UHFFFAOYSA-N 2-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxyethanol Chemical compound C12=CC(OCCO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 NGRLVNLOYHSCOT-UHFFFAOYSA-N 0.000 claims description 6
- COKIRTGHADVGEP-UHFFFAOYSA-N 2-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxypropan-1-ol Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC(CO)C)=CC2=C1 COKIRTGHADVGEP-UHFFFAOYSA-N 0.000 claims description 6
- FPFNTCBEXLWOSS-UHFFFAOYSA-N 2-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxypropanoic acid Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC(C)C(O)=O)=CC2=C1 FPFNTCBEXLWOSS-UHFFFAOYSA-N 0.000 claims description 6
- BJBMPYZXKSTFJM-UHFFFAOYSA-N 2-[5-(1-methoxypropan-2-yloxy)-1-methylindol-3-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC(C)COC)=CC2=C1 BJBMPYZXKSTFJM-UHFFFAOYSA-N 0.000 claims description 6
- KQPOMDOVRNSQIS-UHFFFAOYSA-N 2-[5-methoxy-1-(2-morpholin-4-yl-2-oxoethyl)indol-3-yl]-1h-pyrrolo[2,3-b]pyridine-4-carbonitrile Chemical compound C1=C(C=2NC3=NC=CC(=C3C=2)C#N)C2=CC(OC)=CC=C2N1CC(=O)N1CCOCC1 KQPOMDOVRNSQIS-UHFFFAOYSA-N 0.000 claims description 6
- JJTVNLBIXOXIQR-UHFFFAOYSA-N 4-[2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]-3,5-dimethyl-1,2-oxazole Chemical compound C12=CC(OC)=CC=C2NC=C1C(NC1=NC=C2)=CC1=C2C=1C(C)=NOC=1C JJTVNLBIXOXIQR-UHFFFAOYSA-N 0.000 claims description 6
- NMMCYAVAWKMNJH-UHFFFAOYSA-N 5-methyl-3-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]-1,2,4-oxadiazole Chemical compound O1C(C)=NC(C=2C=C3C(C=4NC5=NC=CC=C5C=4)=CN(C)C3=CC=2)=N1 NMMCYAVAWKMNJH-UHFFFAOYSA-N 0.000 claims description 6
- IZFZUQZBYVWIHC-UHFFFAOYSA-N 6-(1-methylpyrrol-2-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound CN1C=CC=C1C1=CC2=NC=CN=C2N1 IZFZUQZBYVWIHC-UHFFFAOYSA-N 0.000 claims description 6
- TVMUETZKFBUXQB-UHFFFAOYSA-N 6-(3-methylindolizin-1-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC=CN2C(C)=CC(C=3NC4=NC=CN=C4C=3)=C21 TVMUETZKFBUXQB-UHFFFAOYSA-N 0.000 claims description 6
- XQYJBGKMIPFFJS-UHFFFAOYSA-N 6-(4-methoxyphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(OC)=CC=C1C1=CC2=NC=CN=C2N1 XQYJBGKMIPFFJS-UHFFFAOYSA-N 0.000 claims description 6
- DYFHPNQRLTZBCB-UHFFFAOYSA-N 6-(4-methylsulfanylphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(SC)=CC=C1C1=CC2=NC=CN=C2N1 DYFHPNQRLTZBCB-UHFFFAOYSA-N 0.000 claims description 6
- NUKABDWWQOLSDM-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC2=NC=CN=C2N1 NUKABDWWQOLSDM-UHFFFAOYSA-N 0.000 claims description 6
- BOAWWCKJPHLVFL-UHFFFAOYSA-N 6-(5-methoxy-1h-indol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=N1 BOAWWCKJPHLVFL-UHFFFAOYSA-N 0.000 claims description 6
- FCPZMXSDGNBSPP-UHFFFAOYSA-N 6-indolizin-1-yl-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC(C3=C4C=CC=CN4C=C3)=CC2=N1 FCPZMXSDGNBSPP-UHFFFAOYSA-N 0.000 claims description 6
- GIJWLMVJORUCKS-UHFFFAOYSA-N 6-methoxy-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-ol Chemical compound C1=CN=C2NC(C3=CN(C)C=4C=C(C(=CC=43)O)OC)=CC2=C1 GIJWLMVJORUCKS-UHFFFAOYSA-N 0.000 claims description 6
- BHHMPZQRVWVAAR-UHFFFAOYSA-N 7-bromo-8-methylpyrido[2,3-b]pyrazine Chemical compound C1=CN=C2C(C)=C(Br)C=NC2=N1 BHHMPZQRVWVAAR-UHFFFAOYSA-N 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims description 6
- OOVNCCJSGHIIQT-UHFFFAOYSA-N n,1-dimethyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)NC)=CC2=N1 OOVNCCJSGHIIQT-UHFFFAOYSA-N 0.000 claims description 6
- DGTOUUXNYQOLBJ-UHFFFAOYSA-N n-(1,3-dihydroxypropan-2-yl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NC(CO)CO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 DGTOUUXNYQOLBJ-UHFFFAOYSA-N 0.000 claims description 6
- AMECZOITPGYJEM-UHFFFAOYSA-N n-(1-hydroxy-2-methylpropan-2-yl)-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1C(=O)NC(C)(C)CO AMECZOITPGYJEM-UHFFFAOYSA-N 0.000 claims description 6
- DBBLATGZGABQKN-UHFFFAOYSA-N n-(2-hydroxyethyl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NCCO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 DBBLATGZGABQKN-UHFFFAOYSA-N 0.000 claims description 6
- FYCVBBKHRJDKDP-UHFFFAOYSA-N n-(3-amino-3-oxopropyl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-6-carboxamide Chemical compound C12=CC=C(C(=O)NCCC(N)=O)C=C2N(C)C=C1C1=CC2=CC=CN=C2N1 FYCVBBKHRJDKDP-UHFFFAOYSA-N 0.000 claims description 6
- MCEGXLZIVNTQAG-UHFFFAOYSA-N 2-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxyacetic acid Chemical compound C12=CC(OCC(O)=O)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 MCEGXLZIVNTQAG-UHFFFAOYSA-N 0.000 claims description 5
- KERGNDFCTBAMGA-UHFFFAOYSA-N 3-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxypropan-1-ol Chemical compound C12=CC(OCCCO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 KERGNDFCTBAMGA-UHFFFAOYSA-N 0.000 claims description 5
- HQXGRCCXAAELRO-UHFFFAOYSA-N 3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propan-1-amine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=C(CCCN)C2=NC=CN=C2N1 HQXGRCCXAAELRO-UHFFFAOYSA-N 0.000 claims description 5
- PAWSEASAGCSQHU-UHFFFAOYSA-N 4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=CC2=NC=CN=C2N1 PAWSEASAGCSQHU-UHFFFAOYSA-N 0.000 claims description 5
- HEVJMLZQASVXPM-UHFFFAOYSA-N 4-[2-[5,6-dimethoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl]morpholine Chemical compound C1=2C=C(OC)C(OC)=CC=2C(C=2NC3=NC=CC=C3C=2)=CN1CCN1CCOCC1 HEVJMLZQASVXPM-UHFFFAOYSA-N 0.000 claims description 5
- OPIPFYKXYNLMGL-UHFFFAOYSA-N 6-(1-methyl-4-phenylpyrrol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C=1N(C)C=C(C=2NC3=NC=CN=C3C=2)C=1C1=CC=CC=C1 OPIPFYKXYNLMGL-UHFFFAOYSA-N 0.000 claims description 5
- WGWNCAKNPSBPPM-UHFFFAOYSA-N 6-(1-methylindol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C12=CC=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 WGWNCAKNPSBPPM-UHFFFAOYSA-N 0.000 claims description 5
- OUDTUFDECCLCLN-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-7-methyl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C(C)=C1C1=CC=C(C(C)(C)C)C=C1 OUDTUFDECCLCLN-UHFFFAOYSA-N 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 5
- SUVBMZUNTFWEAN-UHFFFAOYSA-N ethyl 2-[2-methoxy-5-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenoxy]acetate Chemical compound C1=C(OC)C(OCC(=O)OCC)=CC(C=2NC3=NC=CN=C3C=2)=C1 SUVBMZUNTFWEAN-UHFFFAOYSA-N 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- NZQQUAQJNADKMN-UHFFFAOYSA-N n-(2-hydroxy-2-methylpropyl)-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1C(=O)NCC(C)(C)O NZQQUAQJNADKMN-UHFFFAOYSA-N 0.000 claims description 5
- IHMYLNCEAZWLKI-UHFFFAOYSA-N n-(2-hydroxyethyl)-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1C(=O)NCCO IHMYLNCEAZWLKI-UHFFFAOYSA-N 0.000 claims description 5
- QXSNZHAWKYWAKB-UHFFFAOYSA-N n-(2-hydroxypropyl)-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1C(=O)NCC(C)O QXSNZHAWKYWAKB-UHFFFAOYSA-N 0.000 claims description 5
- PWQQTIQWOQXEMI-UHFFFAOYSA-N n-(3-amino-3-oxopropyl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NCCC(N)=O)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 PWQQTIQWOQXEMI-UHFFFAOYSA-N 0.000 claims description 5
- SQDCWXJFPMNDRX-UHFFFAOYSA-N n-[3-[3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]propyl]acetamide Chemical compound C12=CC=CC=C2N(CCCNC(=O)C)C=C1C1=CC2=NC=CN=C2N1 SQDCWXJFPMNDRX-UHFFFAOYSA-N 0.000 claims description 5
- VROZAWKQBHASNN-UHFFFAOYSA-N n-methyl-1-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxycyclobutane-1-carboxamide Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=1OC1(C(=O)NC)CCC1 VROZAWKQBHASNN-UHFFFAOYSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 5
- AJCIPCGEQCRBDM-UHFFFAOYSA-N tert-butyl 2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxylate Chemical compound C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=C1C(=O)OC(C)(C)C AJCIPCGEQCRBDM-UHFFFAOYSA-N 0.000 claims description 5
- MUQFTYHVZUPXES-ZDUSSCGKSA-N (2s)-3-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxypropane-1,2-diol Chemical compound C12=CC(OC[C@@H](O)CO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 MUQFTYHVZUPXES-ZDUSSCGKSA-N 0.000 claims description 4
- LXQMHOKEXZETKB-UHFFFAOYSA-N 1-amino-2-methylpropan-2-ol Chemical compound CC(C)(O)CN LXQMHOKEXZETKB-UHFFFAOYSA-N 0.000 claims description 4
- VGGBMWRHJWCWBG-UHFFFAOYSA-N 1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-n-(1h-1,2,4-triazol-5-yl)indole-6-carboxamide Chemical compound C1=C2N(C)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=C1C(=O)NC=1N=CNN=1 VGGBMWRHJWCWBG-UHFFFAOYSA-N 0.000 claims description 4
- NNASJUQMUFFFPP-UHFFFAOYSA-N 1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-amine Chemical compound C12=CC(N)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 NNASJUQMUFFFPP-UHFFFAOYSA-N 0.000 claims description 4
- SZQNDWMUYSGRHG-UHFFFAOYSA-N 1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)-n-(2-thiophen-2-ylethyl)indole-5-carboxamide Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CN=C4C=3)C2=CC=1C(=O)NCCC1=CC=CS1 SZQNDWMUYSGRHG-UHFFFAOYSA-N 0.000 claims description 4
- KGWGSWFHKGVCLZ-UHFFFAOYSA-N 1-methyl-n-[3-(methylamino)-3-oxopropyl]-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)NCCC(=O)NC)=CC2=N1 KGWGSWFHKGVCLZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- DFPXZCFFGKSGGH-UHFFFAOYSA-N 2-(1-methylpyrrol-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound CN1C=CC=C1C1=CC2=CC=CN=C2N1 DFPXZCFFGKSGGH-UHFFFAOYSA-N 0.000 claims description 4
- XRBNURMPSOVRNI-UHFFFAOYSA-N 2-(1h-pyrrol-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CNC(C=2NC3=NC=CC=C3C=2)=C1 XRBNURMPSOVRNI-UHFFFAOYSA-N 0.000 claims description 4
- WPAJCOUYLOSMJP-UHFFFAOYSA-N 2-(4-tert-butylphenyl)-4-chloro-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC2=C(Cl)C=CN=C2N1 WPAJCOUYLOSMJP-UHFFFAOYSA-N 0.000 claims description 4
- JQEYBGCZTGRKPH-UHFFFAOYSA-N 2-(5-methoxy-1-methyl-6-propan-2-yloxyindol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C=3C=4C=C(C(=CC=4N(C)C=3)OC(C)C)OC)=CC2=C1 JQEYBGCZTGRKPH-UHFFFAOYSA-N 0.000 claims description 4
- QSZHVPFODMPGOS-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxylic acid Chemical compound C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=C1C(O)=O QSZHVPFODMPGOS-UHFFFAOYSA-N 0.000 claims description 4
- IGRYIGZITBPHMV-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-3-yl)-n-methyl-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=C(OC)C=C2C(C=3NC=4N=CC=C(C=4C=3)C(=O)NC)=CNC2=C1 IGRYIGZITBPHMV-UHFFFAOYSA-N 0.000 claims description 4
- IGGMDHNFNAGSFW-UHFFFAOYSA-N 2-(5h-pyrrolo[2,3-b]pyrazin-6-yl)quinoline Chemical compound C1=CC=CC2=NC(C3=CC4=NC=CN=C4N3)=CC=C21 IGGMDHNFNAGSFW-UHFFFAOYSA-N 0.000 claims description 4
- DJRQUOXUSPPFSR-UHFFFAOYSA-N 2-[2-methoxy-5-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(OC)=CC=C1C1=CC2=NC=CN=C2N1 DJRQUOXUSPPFSR-UHFFFAOYSA-N 0.000 claims description 4
- VFIDFFAQOVMDBB-UHFFFAOYSA-N 2-[3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]ethanol Chemical compound C12=CC=CC=C2N(CCO)C=C1C1=CC2=NC=CN=C2N1 VFIDFFAQOVMDBB-UHFFFAOYSA-N 0.000 claims description 4
- JPDDXTCUOWHSQE-UHFFFAOYSA-N 2-[5,6-dimethoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-morpholin-4-ylethanone Chemical compound C1=2C=C(OC)C(OC)=CC=2C(C=2NC3=NC=CC=C3C=2)=CN1CC(=O)N1CCOCC1 JPDDXTCUOWHSQE-UHFFFAOYSA-N 0.000 claims description 4
- NVNRNJUWUKDPHD-UHFFFAOYSA-N 2-[5,6-dimethoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetic acid Chemical compound C1=CN=C2NC(C=3C=4C=C(C(=CC=4N(CC(O)=O)C=3)OC)OC)=CC2=C1 NVNRNJUWUKDPHD-UHFFFAOYSA-N 0.000 claims description 4
- AKSKFTWNVYJOKH-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(2-methylquinolin-4-yl)acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NC=4C5=CC=CC=C5N=C(C)C=4)C4=CC=C(C=C43)OC)=CC2=C1 AKSKFTWNVYJOKH-UHFFFAOYSA-N 0.000 claims description 4
- XLDRLTCJIPGWKZ-UHFFFAOYSA-N 2-methoxy-5-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenol Chemical compound C1=C(O)C(OC)=CC=C1C1=CC2=NC=CN=C2N1 XLDRLTCJIPGWKZ-UHFFFAOYSA-N 0.000 claims description 4
- ZHIVJCAOHXULET-UHFFFAOYSA-N 3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)benzaldehyde Chemical compound O=CC1=CC=CC(C=2NC3=NC=CN=C3C=2)=C1 ZHIVJCAOHXULET-UHFFFAOYSA-N 0.000 claims description 4
- WEUYJMOQLNSRHF-UHFFFAOYSA-N 3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)isoquinoline Chemical compound C1=CC=C2C=NC(C3=CC4=NC=CN=C4N3)=CC2=C1 WEUYJMOQLNSRHF-UHFFFAOYSA-N 0.000 claims description 4
- MUQFTYHVZUPXES-UHFFFAOYSA-N 3-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxypropane-1,2-diol Chemical compound C12=CC(OCC(O)CO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 MUQFTYHVZUPXES-UHFFFAOYSA-N 0.000 claims description 4
- NCQLLGRVUVRYAL-UHFFFAOYSA-N 3-[3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]propan-1-amine Chemical compound C12=CC=CC=C2N(CCCN)C=C1C1=CC2=NC=CN=C2N1 NCQLLGRVUVRYAL-UHFFFAOYSA-N 0.000 claims description 4
- CBSWBKLIQDUSCA-UHFFFAOYSA-N 3-[4-(3,5-dimethyl-1,2-oxazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-2-yl]-1h-indole-5-carboxylic acid Chemical compound CC1=NOC(C)=C1C1=CC=NC2=C1C=C(C=1C3=CC(=CC=C3NC=1)C(O)=O)N2 CBSWBKLIQDUSCA-UHFFFAOYSA-N 0.000 claims description 4
- AUWZEPCLXNUNJU-UHFFFAOYSA-N 3-[5-methoxy-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]propan-1-amine Chemical compound C1=CN=C2NC(C3=CN(CCCN)C4=CC=C(C=C43)OC)=CC2=N1 AUWZEPCLXNUNJU-UHFFFAOYSA-N 0.000 claims description 4
- LEKQOMRWKOCLNB-UHFFFAOYSA-N 3-[6-(4-fluorophenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]-n-methylpropanamide Chemical compound N1C2=NC=CN=C2C(CCC(=O)NC)=C1C1=CC=C(F)C=C1 LEKQOMRWKOCLNB-UHFFFAOYSA-N 0.000 claims description 4
- ZZICCIIULWMGFF-UHFFFAOYSA-N 3-[6-(4-methoxyphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]-n-methylpropanamide Chemical compound N1C2=NC=CN=C2C(CCC(=O)NC)=C1C1=CC=C(OC)C=C1 ZZICCIIULWMGFF-UHFFFAOYSA-N 0.000 claims description 4
- FEAXJWJFDJCIMM-UHFFFAOYSA-N 3-[6-(4-methoxyphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propanoic acid Chemical compound C1=CC(OC)=CC=C1C1=C(CCC(O)=O)C2=NC=CN=C2N1 FEAXJWJFDJCIMM-UHFFFAOYSA-N 0.000 claims description 4
- VYADGIBPWMJLTF-UHFFFAOYSA-N 3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propan-1-ol Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=C(CCCO)C2=NC=CN=C2N1 VYADGIBPWMJLTF-UHFFFAOYSA-N 0.000 claims description 4
- PYDLJXBLJBPZNI-UHFFFAOYSA-N 3-methyl-6-(1-methylindol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC=C2C(C3=CC4=NC=C(N=C4N3)C)=CN(C)C2=C1 PYDLJXBLJBPZNI-UHFFFAOYSA-N 0.000 claims description 4
- JZGBONHLJLFZPT-UHFFFAOYSA-N 4-(5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol Chemical compound C1=CC(O)=CC=C1C1=CC2=NC=CN=C2N1 JZGBONHLJLFZPT-UHFFFAOYSA-N 0.000 claims description 4
- RJCNFODBLALXCM-UHFFFAOYSA-N 4-(7-methyl-5h-pyrrolo[2,3-b]pyrazin-6-yl)aniline Chemical compound N1C2=NC=CN=C2C(C)=C1C1=CC=C(N)C=C1 RJCNFODBLALXCM-UHFFFAOYSA-N 0.000 claims description 4
- YKEWIZLNUZNKTF-UHFFFAOYSA-N 4-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]-2-methylbutan-2-ol Chemical compound N1C2=NC=CN=C2C(CCC(C)(O)C)=C1C1=CC=C(C(C)(C)C)C=C1 YKEWIZLNUZNKTF-UHFFFAOYSA-N 0.000 claims description 4
- GUFVOCJZEINPME-UHFFFAOYSA-N 6-(1-benzyl-5-methoxyindol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=C(C=2NC3=NC=CN=C3C=2)C2=CC(OC)=CC=C2N1CC1=CC=CC=C1 GUFVOCJZEINPME-UHFFFAOYSA-N 0.000 claims description 4
- ZVYIHCXPWGXHDU-UHFFFAOYSA-N 6-(1-methylindol-5-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC(C=3C=C4C=CN(C4=CC=3)C)=CC2=N1 ZVYIHCXPWGXHDU-UHFFFAOYSA-N 0.000 claims description 4
- NFCCSXCXRYCSRB-UHFFFAOYSA-N 6-(3,4-dimethoxyphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC2=NC=CN=C2N1 NFCCSXCXRYCSRB-UHFFFAOYSA-N 0.000 claims description 4
- VOYATMLQGSEKER-UHFFFAOYSA-N 6-(3,4-dimethylphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=C(C)C(C)=CC=C1C1=CC2=NC=CN=C2N1 VOYATMLQGSEKER-UHFFFAOYSA-N 0.000 claims description 4
- MFDLPDIVXMMWSI-UHFFFAOYSA-N 6-(3-methoxyphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound COC1=CC=CC(C=2NC3=NC=CN=C3C=2)=C1 MFDLPDIVXMMWSI-UHFFFAOYSA-N 0.000 claims description 4
- ZIPGRNBNZKOCNS-UHFFFAOYSA-N 6-(4-bromophenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(Br)=CC=C1C1=CC2=NC=CN=C2N1 ZIPGRNBNZKOCNS-UHFFFAOYSA-N 0.000 claims description 4
- OGRORAFGBNLUSP-UHFFFAOYSA-N 6-(4-fluorophenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(F)=CC=C1C1=CC2=NC=CN=C2N1 OGRORAFGBNLUSP-UHFFFAOYSA-N 0.000 claims description 4
- SLLSSLGVBCOGEU-UHFFFAOYSA-N 6-[3-(1,3-dioxan-2-yl)phenyl]-5h-pyrrolo[2,3-b]pyrazine Chemical compound O1CCCOC1C1=CC=CC(C=2NC3=NC=CN=C3C=2)=C1 SLLSSLGVBCOGEU-UHFFFAOYSA-N 0.000 claims description 4
- NDHSCNJZSAUAEW-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CC2=NC=CN=C2N1 NDHSCNJZSAUAEW-UHFFFAOYSA-N 0.000 claims description 4
- IXQOVNQMUSNLCC-UHFFFAOYSA-N 6-pyridin-2-yl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C=C1C1=CC=CC=N1 IXQOVNQMUSNLCC-UHFFFAOYSA-N 0.000 claims description 4
- WXNGQLZLJHRZDP-UHFFFAOYSA-N CN(C=C(C1=CC2=NC=CN=C2N1)C1=C2)C1=CC=C2C(O)=O.COC(CNCO)=O Chemical compound CN(C=C(C1=CC2=NC=CN=C2N1)C1=C2)C1=CC=C2C(O)=O.COC(CNCO)=O WXNGQLZLJHRZDP-UHFFFAOYSA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 4
- YYOYJSYGHIOCEG-UHFFFAOYSA-N [1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-5-yl]-morpholin-4-ylmethanone Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CN=C4C=3)C2=CC=1C(=O)N1CCOCC1 YYOYJSYGHIOCEG-UHFFFAOYSA-N 0.000 claims description 4
- SAAPTVBNHZPVGQ-UHFFFAOYSA-N [4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]methanol Chemical compound C1=CC(CO)=CC=C1C1=CC2=NC=CN=C2N1 SAAPTVBNHZPVGQ-UHFFFAOYSA-N 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- PIKSZCHZASBHEM-UHFFFAOYSA-N ethyl 3-[[1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carbonyl]amino]propanoate Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)NCCC(=O)OCC)=CC2=N1 PIKSZCHZASBHEM-UHFFFAOYSA-N 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- SAXZZQKRYZIXGK-UHFFFAOYSA-N n,1-dimethyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)NC)=CC2=C1 SAXZZQKRYZIXGK-UHFFFAOYSA-N 0.000 claims description 4
- OHHAGYLFBKMMNS-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)N(CCO)CCO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 OHHAGYLFBKMMNS-UHFFFAOYSA-N 0.000 claims description 4
- PYMIITKZQGMEBF-UHFFFAOYSA-N n-(2-methoxyethyl)-2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=C(OC)C=C2C(C=3NC=4N=CC=C(C=4C=3)C(=O)NCCOC)=CNC2=C1 PYMIITKZQGMEBF-UHFFFAOYSA-N 0.000 claims description 4
- VGCUIRGNMBJIJN-UHFFFAOYSA-N n-(3-hydroxypropyl)-1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NCCCO)=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 VGCUIRGNMBJIJN-UHFFFAOYSA-N 0.000 claims description 4
- QKFJBWBEBJDNBL-UHFFFAOYSA-N n-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propyl]acetamide Chemical compound N1C2=NC=CN=C2C(CCCNC(=O)C)=C1C1=CC=C(C(C)(C)C)C=C1 QKFJBWBEBJDNBL-UHFFFAOYSA-N 0.000 claims description 4
- ZWAXAAAYMBSOIA-UHFFFAOYSA-N n-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propyl]methanesulfonamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=C(CCCNS(C)(=O)=O)C2=NC=CN=C2N1 ZWAXAAAYMBSOIA-UHFFFAOYSA-N 0.000 claims description 4
- VVPZZIYCYCXVGG-UHFFFAOYSA-N n-[4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CC2=NC=CN=C2N1 VVPZZIYCYCXVGG-UHFFFAOYSA-N 0.000 claims description 4
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- AVMLLCMOHIXKQU-UHFFFAOYSA-M potassium;2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxylate Chemical compound [K+].C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=C1C([O-])=O AVMLLCMOHIXKQU-UHFFFAOYSA-M 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 4
- LHAADVRTPWTUSV-UHFFFAOYSA-N 1-methyl-n-(2-morpholin-4-ylethyl)-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=1C(=O)NCCN1CCOCC1 LHAADVRTPWTUSV-UHFFFAOYSA-N 0.000 claims description 3
- KJSSLGGIYSNMIX-UHFFFAOYSA-N 2-(1-methyl-4-phenylpyrrol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C=1N(C)C=C(C=2NC3=NC=CC=C3C=2)C=1C1=CC=CC=C1 KJSSLGGIYSNMIX-UHFFFAOYSA-N 0.000 claims description 3
- KELLLGDNFSNCIO-UHFFFAOYSA-N 2-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-3-yl)acetonitrile Chemical compound N1C2=NC=CC=C2C(CC#N)=C1C1=CC=CC=C1 KELLLGDNFSNCIO-UHFFFAOYSA-N 0.000 claims description 3
- YRIXXLQLBKMPFS-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C=3N(C)C4=CC=C(C=C4C=3)OC)=CC2=C1 YRIXXLQLBKMPFS-UHFFFAOYSA-N 0.000 claims description 3
- JODRAEBPOHRJGI-UHFFFAOYSA-N 2-[1-methyl-5-(2h-tetrazol-5-yl)indol-3-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=1C=1N=NNN=1 JODRAEBPOHRJGI-UHFFFAOYSA-N 0.000 claims description 3
- KMNMIJBFIPKXKD-UHFFFAOYSA-N 2-[2-methoxy-5-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenoxy]ethanol Chemical compound C1=C(OCCO)C(OC)=CC=C1C1=CC2=NC=CN=C2N1 KMNMIJBFIPKXKD-UHFFFAOYSA-N 0.000 claims description 3
- GOMJCRVLUHYUCB-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-morpholin-4-ylethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCOCC1 GOMJCRVLUHYUCB-UHFFFAOYSA-N 0.000 claims description 3
- BVYQFCOYMRAQQN-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetic acid Chemical compound C1=CN=C2NC(C3=CN(CC(O)=O)C4=CC=C(C=C43)OC)=CC2=C1 BVYQFCOYMRAQQN-UHFFFAOYSA-N 0.000 claims description 3
- BGRKDLVBPMCBJW-UHFFFAOYSA-N 2-ethyltetrazole Chemical compound CCN1N=CN=N1 BGRKDLVBPMCBJW-UHFFFAOYSA-N 0.000 claims description 3
- BQBOHCHMCHLMDK-UHFFFAOYSA-N 3-(4-cyano-1h-pyrrolo[2,3-b]pyridin-2-yl)-1-methylindole-5-carboxylic acid Chemical compound C12=CC(C(O)=O)=CC=C2N(C)C=C1C1=CC2=C(C#N)C=CN=C2N1 BQBOHCHMCHLMDK-UHFFFAOYSA-N 0.000 claims description 3
- HJVIRZPDKZDCRL-UHFFFAOYSA-N 3-[2-(dimethylamino)-5-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]propan-1-ol Chemical compound C1=C(CCCO)C(N(C)C)=CC=C1C1=CC2=NC=CN=C2N1 HJVIRZPDKZDCRL-UHFFFAOYSA-N 0.000 claims description 3
- JLUFLHFTAWTMKE-UHFFFAOYSA-N 3-[2-(dimethylamino)-5-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]propanoic acid Chemical compound C1=C(CCC(O)=O)C(N(C)C)=CC=C1C1=CC2=NC=CN=C2N1 JLUFLHFTAWTMKE-UHFFFAOYSA-N 0.000 claims description 3
- YXOCECKDUCUKPX-UHFFFAOYSA-N 3-[6-(4-fluorophenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propanoic acid Chemical compound N1C2=NC=CN=C2C(CCC(=O)O)=C1C1=CC=C(F)C=C1 YXOCECKDUCUKPX-UHFFFAOYSA-N 0.000 claims description 3
- MTTCOBLSWWQVDL-UHFFFAOYSA-N 3-fluoro-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C(F)=C1C1=CN(C)C2=CC=C(OC)C=C21 MTTCOBLSWWQVDL-UHFFFAOYSA-N 0.000 claims description 3
- OZRZOPXIQIDGSR-UHFFFAOYSA-N 4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1C1=CC2=NC=CN=C2N1 OZRZOPXIQIDGSR-UHFFFAOYSA-N 0.000 claims description 3
- HEXWGHMYABJLGV-UHFFFAOYSA-N 5-methoxy-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-6-ol Chemical compound C1=CN=C2NC(C=3C=4C=C(C(=CC=4N(C)C=3)O)OC)=CC2=C1 HEXWGHMYABJLGV-UHFFFAOYSA-N 0.000 claims description 3
- UJGWDQOREZNCCC-UHFFFAOYSA-N 6-(1-methyl-5-phenylpyrazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine Chemical compound CN1N=C(C=2NC3=NC=CN=C3C=2)C=C1C1=CC=CC=C1 UJGWDQOREZNCCC-UHFFFAOYSA-N 0.000 claims description 3
- NSROKWNOZRNWPF-UHFFFAOYSA-N 6-(1-methylindazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine Chemical compound C12=CC=CC=C2N(C)N=C1C1=CC2=NC=CN=C2N1 NSROKWNOZRNWPF-UHFFFAOYSA-N 0.000 claims description 3
- QUDOYZVSZNJAJI-UHFFFAOYSA-N 6-(1-methylpyrrol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound CN1C=CC(C=2NC3=NC=CN=C3C=2)=C1 QUDOYZVSZNJAJI-UHFFFAOYSA-N 0.000 claims description 3
- WPZBQHHKIFAYMT-UHFFFAOYSA-N 6-(2-chloro-5-methoxy-1-methylindol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC(C3=C(Cl)N(C)C4=CC=C(C=C43)OC)=CC2=N1 WPZBQHHKIFAYMT-UHFFFAOYSA-N 0.000 claims description 3
- OCDUBFIMRNXMGM-UHFFFAOYSA-N 6-(3-bromophenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound BrC1=CC=CC(C=2NC3=NC=CN=C3C=2)=C1 OCDUBFIMRNXMGM-UHFFFAOYSA-N 0.000 claims description 3
- ZNIORXXXAJEYQH-UHFFFAOYSA-N 6-(4-methylsulfinylphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(S(=O)C)=CC=C1C1=CC2=NC=CN=C2N1 ZNIORXXXAJEYQH-UHFFFAOYSA-N 0.000 claims description 3
- VPRBEBVRGIGTGF-UHFFFAOYSA-N 6-(4-methylsulfonylphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC2=NC=CN=C2N1 VPRBEBVRGIGTGF-UHFFFAOYSA-N 0.000 claims description 3
- YEYZRVNDUWRTNQ-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-7-prop-1-enyl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C(C=CC)=C1C1=CC=C(C(C)(C)C)C=C1 YEYZRVNDUWRTNQ-UHFFFAOYSA-N 0.000 claims description 3
- RQFHBMHSUJNCTI-UHFFFAOYSA-N 6-(5,6,7,8-tetrahydroindolizin-1-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC(C=3C=CN4CCCCC4=3)=CC2=N1 RQFHBMHSUJNCTI-UHFFFAOYSA-N 0.000 claims description 3
- SILSHTRJCCPNFE-UHFFFAOYSA-N 6-(furan-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound O1C=CC(C=2NC3=NC=CN=C3C=2)=C1 SILSHTRJCCPNFE-UHFFFAOYSA-N 0.000 claims description 3
- RNHXCQLEULNFPV-UHFFFAOYSA-N 6-[1-(3-pyridin-3-yloxypropyl)indol-3-yl]-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=C(C=2NC3=NC=CN=C3C=2)C2=CC=CC=C2N1CCCOC1=CC=CN=C1 RNHXCQLEULNFPV-UHFFFAOYSA-N 0.000 claims description 3
- KGGPSBLELUHYKI-UHFFFAOYSA-N 6-[4-(1,3-dioxan-2-yl)phenyl]-5h-pyrrolo[2,3-b]pyrazine Chemical compound O1CCCOC1C1=CC=C(C=2NC3=NC=CN=C3C=2)C=C1 KGGPSBLELUHYKI-UHFFFAOYSA-N 0.000 claims description 3
- LVARNOHOOZOAGQ-UHFFFAOYSA-N 6-phenyl-7-propan-2-yl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C(C(C)C)=C1C1=CC=CC=C1 LVARNOHOOZOAGQ-UHFFFAOYSA-N 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- JARHJDCLSBJTAX-UHFFFAOYSA-N [1-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxycyclobutyl]methanol Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=1OC1(CO)CCC1 JARHJDCLSBJTAX-UHFFFAOYSA-N 0.000 claims description 3
- XIHWGXJGOTZLIG-UHFFFAOYSA-N [1-[5-[1-(hydroxymethyl)cyclobutyl]oxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]cyclobutyl]methanol Chemical compound C=1C=C2N(C3(CO)CCC3)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=1OC1(CO)CCC1 XIHWGXJGOTZLIG-UHFFFAOYSA-N 0.000 claims description 3
- CWEMKTADLXMJOP-UHFFFAOYSA-N [3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]methanol Chemical compound OCC1=CC=CC(C=2NC3=NC=CN=C3C=2)=C1 CWEMKTADLXMJOP-UHFFFAOYSA-N 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- YORCGQINTQQCTH-UHFFFAOYSA-N n,1-dimethyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-amine Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)NC)=CC2=C1 YORCGQINTQQCTH-UHFFFAOYSA-N 0.000 claims description 3
- OOWFNUNLQJGMIX-UHFFFAOYSA-N n,n,1-trimethyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)N(C)C)=CC2=N1 OOWFNUNLQJGMIX-UHFFFAOYSA-N 0.000 claims description 3
- RIYDZDVMOLPOSA-UHFFFAOYSA-N n-(1,3-dihydroxy-2-methylpropan-2-yl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NC(C)(CO)CO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 RIYDZDVMOLPOSA-UHFFFAOYSA-N 0.000 claims description 3
- GQZGUPUPTQVLPU-UHFFFAOYSA-N n-(1,3-dihydroxypropan-2-yl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-6-carboxamide Chemical compound C12=CC=C(C(=O)NC(CO)CO)C=C2N(C)C=C1C1=CC2=CC=CN=C2N1 GQZGUPUPTQVLPU-UHFFFAOYSA-N 0.000 claims description 3
- OEXSEKPUBPFSBH-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NCC(O)CO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 OEXSEKPUBPFSBH-UHFFFAOYSA-N 0.000 claims description 3
- IARCJGCMPYDUMM-UHFFFAOYSA-N n-(2-fluoroethyl)-1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NCCF)=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 IARCJGCMPYDUMM-UHFFFAOYSA-N 0.000 claims description 3
- FOMSGDOUGOTANG-UHFFFAOYSA-N n-(2-hydroxyethyl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-6-carboxamide Chemical compound C12=CC=C(C(=O)NCCO)C=C2N(C)C=C1C1=CC2=CC=CN=C2N1 FOMSGDOUGOTANG-UHFFFAOYSA-N 0.000 claims description 3
- DXDHILMEBJRQBQ-UHFFFAOYSA-N n-[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NC(CO)(CO)CO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 DXDHILMEBJRQBQ-UHFFFAOYSA-N 0.000 claims description 3
- LMQAALQEYGOOIO-UHFFFAOYSA-N n-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]methanesulfonamide Chemical compound C12=CC(NS(C)(=O)=O)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 LMQAALQEYGOOIO-UHFFFAOYSA-N 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- GPHQHTOMRSGBNZ-UHFFFAOYSA-N pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC=C1 GPHQHTOMRSGBNZ-UHFFFAOYSA-N 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- KZJLTGRDWWXYHJ-UHFFFAOYSA-N 1-(2,5-dihydropyrrol-1-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CC=CC1 KZJLTGRDWWXYHJ-UHFFFAOYSA-N 0.000 claims description 2
- UCPREHUNIGUZHI-UHFFFAOYSA-N 1-(2,6-dimethylmorpholin-4-yl)-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]ethanone Chemical compound C1C(C)OC(C)CN1C(=O)CN1C(C=2NC3=NC=CC=C3C=2)=CC=C1 UCPREHUNIGUZHI-UHFFFAOYSA-N 0.000 claims description 2
- LVTUIWBHHMEGKI-UHFFFAOYSA-N 1-(2,6-dimethylmorpholin-4-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CC(C)OC(C)C1 LVTUIWBHHMEGKI-UHFFFAOYSA-N 0.000 claims description 2
- OCESAMICSQEKCC-UHFFFAOYSA-N 1-(3,3-dimethylpiperidin-1-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCCC(C)(C)C1 OCESAMICSQEKCC-UHFFFAOYSA-N 0.000 claims description 2
- DDWNQFWAEZKZHO-UHFFFAOYSA-N 1-(3,6-dihydro-2h-pyridin-1-yl)-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]ethanone Chemical compound C1=CC=C(C=2NC3=NC=CC=C3C=2)N1CC(=O)N1CCC=CC1 DDWNQFWAEZKZHO-UHFFFAOYSA-N 0.000 claims description 2
- XHVDYZJWVTWBCD-UHFFFAOYSA-N 1-(3,6-dihydro-2h-pyridin-1-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCC=CC1 XHVDYZJWVTWBCD-UHFFFAOYSA-N 0.000 claims description 2
- HXVXATGYSIUQDR-UHFFFAOYSA-N 1-(4-benzhydrylpiperazin-1-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 HXVXATGYSIUQDR-UHFFFAOYSA-N 0.000 claims description 2
- WXYLXNBCVLDZAR-UHFFFAOYSA-N 1-(4-benzylpiperazin-1-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCN1CC1=CC=CC=C1 WXYLXNBCVLDZAR-UHFFFAOYSA-N 0.000 claims description 2
- LXIYPROGDBDNIS-UHFFFAOYSA-N 1-(4-hydroxypiperidin-1-yl)-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]ethanone Chemical compound C1CC(O)CCN1C(=O)CN1C(C=2NC3=NC=CC=C3C=2)=CC=C1 LXIYPROGDBDNIS-UHFFFAOYSA-N 0.000 claims description 2
- QUFQKOIFRJLLKN-UHFFFAOYSA-N 1-(4-hydroxypiperidin-1-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCC(O)CC1 QUFQKOIFRJLLKN-UHFFFAOYSA-N 0.000 claims description 2
- PXZVUUSOHKXROL-UHFFFAOYSA-N 1-(4-methylpiperazin-1-yl)-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]ethanone Chemical compound C1CN(C)CCN1C(=O)CN1C(C=2NC3=NC=CC=C3C=2)=CC=C1 PXZVUUSOHKXROL-UHFFFAOYSA-N 0.000 claims description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 2
- YHLFECNDYJLXSZ-UHFFFAOYSA-N 1-[4-(2-methoxyethyl)piperazin-1-yl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1CN(CCOC)CCN1C(=O)CN1C2=CC=C(OC)C=C2C(C=2NC3=NC=CC=C3C=2)=C1 YHLFECNDYJLXSZ-UHFFFAOYSA-N 0.000 claims description 2
- VRGGJGJITGEMAJ-UHFFFAOYSA-N 1-[4-(3-hydroxyphenyl)piperazin-1-yl]-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]ethanone Chemical compound OC1=CC=CC(N2CCN(CC2)C(=O)CN2C(=CC=C2)C=2NC3=NC=CC=C3C=2)=C1 VRGGJGJITGEMAJ-UHFFFAOYSA-N 0.000 claims description 2
- NMVFMXDULQPROQ-UHFFFAOYSA-N 1-[4-(4-methoxyphenyl)piperazin-1-yl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=CC(OC)=CC=C1N1CCN(C(=O)CN2C3=CC=C(OC)C=C3C(C=3NC4=NC=CC=C4C=3)=C2)CC1 NMVFMXDULQPROQ-UHFFFAOYSA-N 0.000 claims description 2
- ZLMRGHXNFAWRDV-UHFFFAOYSA-N 1-[4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C1=CC2=NC=CN=C2N1 ZLMRGHXNFAWRDV-UHFFFAOYSA-N 0.000 claims description 2
- RHYQATNAXYUWJU-UHFFFAOYSA-N 1-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCN1CC1=CC=C(Cl)C=C1 RHYQATNAXYUWJU-UHFFFAOYSA-N 0.000 claims description 2
- MRBZEZBWAHYDSR-UHFFFAOYSA-N 1-[4-[(4-tert-butylphenyl)methyl]piperazin-1-yl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCN1CC1=CC=C(C(C)(C)C)C=C1 MRBZEZBWAHYDSR-UHFFFAOYSA-N 0.000 claims description 2
- KSIZKFJYVIZTDJ-UHFFFAOYSA-N 1-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCN(CCN(C)C)CC1 KSIZKFJYVIZTDJ-UHFFFAOYSA-N 0.000 claims description 2
- BAIMGIJCZXNMGZ-UHFFFAOYSA-N 1-[4-[3-(dimethylamino)propyl]piperazin-1-yl]-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]ethanone Chemical compound C1CN(CCCN(C)C)CCN1C(=O)CN1C(C=2NC3=NC=CC=C3C=2)=CC=C1 BAIMGIJCZXNMGZ-UHFFFAOYSA-N 0.000 claims description 2
- DFHPOROHGLPIEI-UHFFFAOYSA-N 1-methyl-4-[2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]acetyl]piperazin-2-one Chemical compound C1C(=O)N(C)CCN1C(=O)CN1C(C=2NC3=NC=CC=C3C=2)=CC=C1 DFHPOROHGLPIEI-UHFFFAOYSA-N 0.000 claims description 2
- QPQYJHKPANJWSN-UHFFFAOYSA-N 2-(1-ethyl-5-methoxyindol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxylic acid Chemical compound C12=CC(OC)=CC=C2N(CC)C=C1C1=CC2=C(C(O)=O)C=CN=C2N1 QPQYJHKPANJWSN-UHFFFAOYSA-N 0.000 claims description 2
- RYWGGRZTKNVSPR-UHFFFAOYSA-N 2-(1-methyl-5-pyridin-4-ylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=1C1=CC=NC=C1 RYWGGRZTKNVSPR-UHFFFAOYSA-N 0.000 claims description 2
- QOWCSDWRCIPYJJ-UHFFFAOYSA-N 2-(4-bromophenyl)-3-methyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C(C)=C1C1=CC=C(Br)C=C1 QOWCSDWRCIPYJJ-UHFFFAOYSA-N 0.000 claims description 2
- PAUWEYGKUDICMQ-UHFFFAOYSA-N 2-(4-chlorophenyl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(Cl)=CC=C1C1=CC2=CC=CN=C2N1 PAUWEYGKUDICMQ-UHFFFAOYSA-N 0.000 claims description 2
- LTFUDAWTAOIQCP-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-4-piperidin-1-yl-1h-pyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2N1CCCCC1 LTFUDAWTAOIQCP-UHFFFAOYSA-N 0.000 claims description 2
- YKOZAXNYUUUUGV-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-n-(2-methylphenyl)-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2NC1=CC=CC=C1C YKOZAXNYUUUUGV-UHFFFAOYSA-N 0.000 claims description 2
- HFGVNZBYHIWWFF-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-n-(3-methylphenyl)-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2NC1=CC=CC(C)=C1 HFGVNZBYHIWWFF-UHFFFAOYSA-N 0.000 claims description 2
- DEUZHMAECLRWHP-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-n-(4-methylphenyl)-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2NC1=CC=C(C)C=C1 DEUZHMAECLRWHP-UHFFFAOYSA-N 0.000 claims description 2
- NXWDZEUHBORAJK-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-n-phenyl-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2NC1=CC=CC=C1 NXWDZEUHBORAJK-UHFFFAOYSA-N 0.000 claims description 2
- KGQLZBXQDDLVNZ-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=C1C(N)=O KGQLZBXQDDLVNZ-UHFFFAOYSA-N 0.000 claims description 2
- WHPGREASCBBEAV-UHFFFAOYSA-N 2-(6-phenyl-5h-pyrrolo[2,3-b]pyrazin-7-yl)ethanol Chemical compound N1C2=NC=CN=C2C(CCO)=C1C1=CC=CC=C1 WHPGREASCBBEAV-UHFFFAOYSA-N 0.000 claims description 2
- KPUOXMBOZWPIBK-UHFFFAOYSA-N 2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]-1-thiomorpholin-4-ylethanone Chemical compound C1=CC=C(C=2NC3=NC=CC=C3C=2)N1CC(=O)N1CCSCC1 KPUOXMBOZWPIBK-UHFFFAOYSA-N 0.000 claims description 2
- TZZCKBOVBQPDIU-UHFFFAOYSA-N 2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=CC=C1C1=CC2=CC=CN=C2N1 TZZCKBOVBQPDIU-UHFFFAOYSA-N 0.000 claims description 2
- BPJQLQMFOWMKNO-UHFFFAOYSA-N 2-[4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]propan-2-ol Chemical compound C1=CC(C(C)(O)C)=CC=C1C1=CC2=NC=CN=C2N1 BPJQLQMFOWMKNO-UHFFFAOYSA-N 0.000 claims description 2
- JFOZGRYEVSDSGW-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-(1,3-thiazolidin-3-yl)ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCSC1 JFOZGRYEVSDSGW-UHFFFAOYSA-N 0.000 claims description 2
- OEJANAGBQNONLV-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-(3-methylpiperazin-1-yl)ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCNC(C)C1 OEJANAGBQNONLV-UHFFFAOYSA-N 0.000 claims description 2
- HOFKRAALLCHRDQ-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-[4-(1-phenylethyl)piperazin-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCN1C(C)C1=CC=CC=C1 HOFKRAALLCHRDQ-UHFFFAOYSA-N 0.000 claims description 2
- BXPYGBUPFAJHEM-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCN1CCN1CCOCC1 BXPYGBUPFAJHEM-UHFFFAOYSA-N 0.000 claims description 2
- DYOUPYMZDDHSEF-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-[4-(3-methylphenyl)piperazin-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCN1C1=CC=CC(C)=C1 DYOUPYMZDDHSEF-UHFFFAOYSA-N 0.000 claims description 2
- ACZHQUXATMMPLP-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-[4-(oxolane-2-carbonyl)piperazin-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCN1C(=O)C1CCCO1 ACZHQUXATMMPLP-UHFFFAOYSA-N 0.000 claims description 2
- XMXDQCRUWXHMBD-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-piperidin-1-ylethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCCCC1 XMXDQCRUWXHMBD-UHFFFAOYSA-N 0.000 claims description 2
- NELKYKMFCBJEKH-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-pyrrolidin-1-ylethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCCC1 NELKYKMFCBJEKH-UHFFFAOYSA-N 0.000 claims description 2
- PNQZHGQOQVJUFV-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-thiomorpholin-4-ylethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCSCC1 PNQZHGQOQVJUFV-UHFFFAOYSA-N 0.000 claims description 2
- OVMCATWJGAKILF-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(2-methylcyclohexyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC1CCCCC1C OVMCATWJGAKILF-UHFFFAOYSA-N 0.000 claims description 2
- DYJCPBAQGVSXMD-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(2-phenylsulfanylethyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCSC1=CC=CC=C1 DYJCPBAQGVSXMD-UHFFFAOYSA-N 0.000 claims description 2
- XBGORNDCEPLSDY-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(2-pyridin-4-ylethyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCC1=CC=NC=C1 XBGORNDCEPLSDY-UHFFFAOYSA-N 0.000 claims description 2
- HMDOBUOYJXHSQG-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(2-pyrrolidin-1-ylethyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCN1CCCC1 HMDOBUOYJXHSQG-UHFFFAOYSA-N 0.000 claims description 2
- IFOXNFQUBVQIBF-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(3-oxo-1,2-oxazolidin-4-yl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC1CONC1=O IFOXNFQUBVQIBF-UHFFFAOYSA-N 0.000 claims description 2
- RUQQVNMGWNCECS-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(3-pyrrolidin-1-ylpropyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCCN1CCCC1 RUQQVNMGWNCECS-UHFFFAOYSA-N 0.000 claims description 2
- BGIPIZFHVWJSCZ-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(4-morpholin-4-ylphenyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC(C=C1)=CC=C1N1CCOCC1 BGIPIZFHVWJSCZ-UHFFFAOYSA-N 0.000 claims description 2
- NCYPGKCZJOISEV-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(pyridin-2-ylmethyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCC1=CC=CC=N1 NCYPGKCZJOISEV-UHFFFAOYSA-N 0.000 claims description 2
- LOFRLFDLBCLBOZ-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-[3-(2-oxopyrrolidin-1-yl)propyl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCCN1CCCC1=O LOFRLFDLBCLBOZ-UHFFFAOYSA-N 0.000 claims description 2
- FKVQFHKOOGPTLG-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-[3-(4-methylpiperazin-1-yl)propyl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCCN1CCN(C)CC1 FKVQFHKOOGPTLG-UHFFFAOYSA-N 0.000 claims description 2
- SUOVCTWFKJKPPB-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-methyl-n-(pyridin-3-ylmethyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(C)CC1=CC=CN=C1 SUOVCTWFKJKPPB-UHFFFAOYSA-N 0.000 claims description 2
- XVYFBCKOJVBDOF-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-quinolin-3-ylacetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NC=4C=C5C=CC=CC5=NC=4)C4=CC=C(C=C43)OC)=CC2=C1 XVYFBCKOJVBDOF-UHFFFAOYSA-N 0.000 claims description 2
- HOOLUHYVJBFGFY-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-quinolin-8-ylacetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NC=4C5=NC=CC=C5C=CC=4)C4=CC=C(C=C43)OC)=CC2=C1 HOOLUHYVJBFGFY-UHFFFAOYSA-N 0.000 claims description 2
- SYQBBYQZKLRCRP-UHFFFAOYSA-N 2-[cyclopropyl-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]amino]acetaldehyde Chemical compound C1=CC=C(C=2NC3=NC=CC=C3C=2)N1N(CC=O)C1CC1 SYQBBYQZKLRCRP-UHFFFAOYSA-N 0.000 claims description 2
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 claims description 2
- MTEZLAATISORQK-UHFFFAOYSA-N 2-methoxyacetamide Chemical compound COCC(N)=O MTEZLAATISORQK-UHFFFAOYSA-N 0.000 claims description 2
- PPWLAQVKIFDULF-UHFFFAOYSA-N 2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C=C1C1=CC=CC=C1 PPWLAQVKIFDULF-UHFFFAOYSA-N 0.000 claims description 2
- MMLMJZNNELPPNV-UHFFFAOYSA-N 2-phenyl-1h-pyrrolo[2,3-b]pyridine-3-carbaldehyde Chemical compound N1C2=NC=CC=C2C(C=O)=C1C1=CC=CC=C1 MMLMJZNNELPPNV-UHFFFAOYSA-N 0.000 claims description 2
- OGCFKNMRJGBFPU-UHFFFAOYSA-N 2-phenyl-3-prop-1-enyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C(C=CC)=C1C1=CC=CC=C1 OGCFKNMRJGBFPU-UHFFFAOYSA-N 0.000 claims description 2
- ALSYTSCUTDAYIU-UHFFFAOYSA-N 2-pyridin-3-yl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C=C1C1=CC=CN=C1 ALSYTSCUTDAYIU-UHFFFAOYSA-N 0.000 claims description 2
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- SWSNYMMQZWVXAI-UHFFFAOYSA-N 3-(4-chloro-1h-pyrrolo[2,3-b]pyridin-2-yl)-1-methylindole-5-carboxylic acid Chemical compound C12=CC(C(O)=O)=CC=C2N(C)C=C1C1=CC2=C(Cl)C=CN=C2N1 SWSNYMMQZWVXAI-UHFFFAOYSA-N 0.000 claims description 2
- RBLSJYMBJFUGLJ-UHFFFAOYSA-N 3-[5-methoxy-2-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-(4-methylpiperazin-1-yl)propan-1-one Chemical compound C=1C2=CC=CN=C2NC=1C1=CC2=CC(OC)=CC=C2N1CCC(=O)N1CCN(C)CC1 RBLSJYMBJFUGLJ-UHFFFAOYSA-N 0.000 claims description 2
- QUWWKACRKZQBDN-UHFFFAOYSA-N 3-[5-methoxy-2-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-morpholin-4-ylpropan-1-one Chemical compound C=1C2=CC=CN=C2NC=1C1=CC2=CC(OC)=CC=C2N1CCC(=O)N1CCOCC1 QUWWKACRKZQBDN-UHFFFAOYSA-N 0.000 claims description 2
- SLCKPMRGVFIKEG-UHFFFAOYSA-N 3-[5-methoxy-2-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-thiomorpholin-4-ylpropan-1-one Chemical compound C=1C2=CC=CN=C2NC=1C1=CC2=CC(OC)=CC=C2N1CCC(=O)N1CCSCC1 SLCKPMRGVFIKEG-UHFFFAOYSA-N 0.000 claims description 2
- AVWZPCHWSSWCFA-UHFFFAOYSA-N 3-[5-methoxy-2-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-phenylpropanamide Chemical compound C=1C2=CC=CN=C2NC=1C1=CC2=CC(OC)=CC=C2N1CCC(=O)NC1=CC=CC=C1 AVWZPCHWSSWCFA-UHFFFAOYSA-N 0.000 claims description 2
- HUUVWAZMMHDJAT-UHFFFAOYSA-N 3-[5-methoxy-2-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propanoic acid Chemical compound C1=CN=C2NC(C=3N(CCC(O)=O)C4=CC=C(C=C4C=3)OC)=CC2=C1 HUUVWAZMMHDJAT-UHFFFAOYSA-N 0.000 claims description 2
- OAPAMBQQVWOUSF-UHFFFAOYSA-N 3-[6-(4-hydroxyphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]-N-methylpropanamide Chemical compound N1C2=NC=CN=C2C(CCC(=O)NC)=C1C1=CC=C(O)C=C1 OAPAMBQQVWOUSF-UHFFFAOYSA-N 0.000 claims description 2
- RKISGCJJBSZNEN-UHFFFAOYSA-N 3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]-n,n-dimethylpropanamide Chemical compound N1C2=NC=CN=C2C(CCC(=O)N(C)C)=C1C1=CC=C(C(C)(C)C)C=C1 RKISGCJJBSZNEN-UHFFFAOYSA-N 0.000 claims description 2
- AYJCGTRIBDXSHI-UHFFFAOYSA-N 3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]-n-methylpropanamide Chemical compound N1C2=NC=CN=C2C(CCC(=O)NC)=C1C1=CC=C(C(C)(C)C)C=C1 AYJCGTRIBDXSHI-UHFFFAOYSA-N 0.000 claims description 2
- IZJXUOPCDJBMST-UHFFFAOYSA-N 3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propanenitrile Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=C(CCC#N)C2=NC=CN=C2N1 IZJXUOPCDJBMST-UHFFFAOYSA-N 0.000 claims description 2
- RDGODMUTJJJLBX-UHFFFAOYSA-N 3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propanoic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=C(CCC(O)=O)C2=NC=CN=C2N1 RDGODMUTJJJLBX-UHFFFAOYSA-N 0.000 claims description 2
- LDSHIDJQYWKFKI-UHFFFAOYSA-N 3-methyl-5-phenylpentanamide Chemical compound NC(=O)CC(C)CCC1=CC=CC=C1 LDSHIDJQYWKFKI-UHFFFAOYSA-N 0.000 claims description 2
- WOSGPBFDGVRZKT-UHFFFAOYSA-N 3-methyl-6-phenyl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC(C)=CN=C2C=C1C1=CC=CC=C1 WOSGPBFDGVRZKT-UHFFFAOYSA-N 0.000 claims description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- CNJGCQXKBAUFNA-UHFFFAOYSA-N 4-(3-methyl-1h-pyrrolo[2,3-b]pyridin-2-yl)benzoic acid Chemical compound N1C2=NC=CC=C2C(C)=C1C1=CC=C(C(O)=O)C=C1 CNJGCQXKBAUFNA-UHFFFAOYSA-N 0.000 claims description 2
- RMSBSMVCSMWZST-UHFFFAOYSA-N 4-[(2-phenyl-1h-pyrrolo[2,3-b]pyridin-3-yl)methyl]morpholine Chemical compound C=1C=CC=CC=1C=1NC2=NC=CC=C2C=1CN1CCOCC1 RMSBSMVCSMWZST-UHFFFAOYSA-N 0.000 claims description 2
- XMFLIOYKQXKSHH-UHFFFAOYSA-N 4-[2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]morpholine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2N1CCOCC1 XMFLIOYKQXKSHH-UHFFFAOYSA-N 0.000 claims description 2
- YJKOKOAXYWZUHF-UHFFFAOYSA-N 4-[2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]acetyl]piperazin-2-one Chemical compound C1=CC=C(C=2NC3=NC=CC=C3C=2)N1CC(=O)N1CCNC(=O)C1 YJKOKOAXYWZUHF-UHFFFAOYSA-N 0.000 claims description 2
- QMXXYNQIJANUME-UHFFFAOYSA-N 4-[2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetyl]-1-methylpiperazin-2-one Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCN(C)C(=O)C1 QMXXYNQIJANUME-UHFFFAOYSA-N 0.000 claims description 2
- JCTPCFDGUQRJON-UHFFFAOYSA-N 4-[2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetyl]-3,3-dimethylpiperazin-2-one Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCNC(=O)C1(C)C JCTPCFDGUQRJON-UHFFFAOYSA-N 0.000 claims description 2
- XPDBSYYQEBBVHZ-UHFFFAOYSA-N 4-[3-[3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]propyl]morpholine Chemical compound C1=C(C=2NC3=NC=CN=C3C=2)C2=CC=CC=C2N1CCCN1CCOCC1 XPDBSYYQEBBVHZ-UHFFFAOYSA-N 0.000 claims description 2
- QCYZWVVKBMGGBM-UHFFFAOYSA-N 4-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]butan-2-one Chemical compound N1C2=NC=CN=C2C(CCC(=O)C)=C1C1=CC=C(C(C)(C)C)C=C1 QCYZWVVKBMGGBM-UHFFFAOYSA-N 0.000 claims description 2
- PPRZWBLCPANUPB-UHFFFAOYSA-N 4-methyl-2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound C=1C=2C(C)=CC=NC=2NC=1C1=CC=CC=C1 PPRZWBLCPANUPB-UHFFFAOYSA-N 0.000 claims description 2
- LQAFCJAXORNEHL-UHFFFAOYSA-N 5-methyl-2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound C=1C2=CC(C)=CN=C2NC=1C1=CC=CC=C1 LQAFCJAXORNEHL-UHFFFAOYSA-N 0.000 claims description 2
- PKNKYWXKDIEEGA-UHFFFAOYSA-N 6-(1-methyl-2-phenylpyrrol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound CN1C=CC(C=2NC3=NC=CN=C3C=2)=C1C1=CC=CC=C1 PKNKYWXKDIEEGA-UHFFFAOYSA-N 0.000 claims description 2
- YGINNQXWHUWSHG-UHFFFAOYSA-N 6-(2-chlorophenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound ClC1=CC=CC=C1C1=CC2=NC=CN=C2N1 YGINNQXWHUWSHG-UHFFFAOYSA-N 0.000 claims description 2
- VWKKNDNFMQEZPN-UHFFFAOYSA-N 6-(4-piperazin-1-ylphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1CNCCN1C1=CC=C(C=2NC3=NC=CN=C3C=2)C=C1 VWKKNDNFMQEZPN-UHFFFAOYSA-N 0.000 claims description 2
- IQFCDWGPPITEID-UHFFFAOYSA-N 6-(4-pyrrolidin-1-ylphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1CCCN1C1=CC=C(C=2NC3=NC=CN=C3C=2)C=C1 IQFCDWGPPITEID-UHFFFAOYSA-N 0.000 claims description 2
- UIHGKHKSOZXFRS-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-7-(2-ethyltetrazol-5-yl)-5H-pyrrolo[2,3-b]pyrazine Chemical compound CCn1nnc(n1)-c1c([nH]c2nccnc12)-c1ccc(cc1)C(C)(C)C UIHGKHKSOZXFRS-UHFFFAOYSA-N 0.000 claims description 2
- KHKWNJPABRVFFN-UHFFFAOYSA-N 6-[4-(furan-2-yl)phenyl]-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=COC(C=2C=CC(=CC=2)C=2NC3=NC=CN=C3C=2)=C1 KHKWNJPABRVFFN-UHFFFAOYSA-N 0.000 claims description 2
- AJBVUUPNIOLPFS-UHFFFAOYSA-N 6-chloro-2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC(Cl)=CC=C2C=C1C1=CC=CC=C1 AJBVUUPNIOLPFS-UHFFFAOYSA-N 0.000 claims description 2
- KILYBYFBRWDGTM-UHFFFAOYSA-N 6-chloro-4-methyl-2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound C=1C=2C(C)=CC(Cl)=NC=2NC=1C1=CC=CC=C1 KILYBYFBRWDGTM-UHFFFAOYSA-N 0.000 claims description 2
- ONJMAXYFHBVNTH-UHFFFAOYSA-N 6-phenyl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C=C1C1=CC=CC=C1 ONJMAXYFHBVNTH-UHFFFAOYSA-N 0.000 claims description 2
- QLBVJDQLXOSSMT-UHFFFAOYSA-N 7-methyl-6-phenyl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C(C)=C1C1=CC=CC=C1 QLBVJDQLXOSSMT-UHFFFAOYSA-N 0.000 claims description 2
- IUIJQJGEIGFGIM-UHFFFAOYSA-N C1=CC(Br)=CC=C1C(N1)=CN=C2C1=CC=N2 Chemical compound C1=CC(Br)=CC=C1C(N1)=CN=C2C1=CC=N2 IUIJQJGEIGFGIM-UHFFFAOYSA-N 0.000 claims description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 206010011686 Cutaneous vasculitis Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- UGHVSNVFYBZSLH-UHFFFAOYSA-N [1-[1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-5-yl]oxycyclobutyl]methanol Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CN=C4C=3)C2=CC=1OC1(CO)CCC1 UGHVSNVFYBZSLH-UHFFFAOYSA-N 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- KUMRTJNGPLSWHP-UHFFFAOYSA-N ethyl 3-[6-(4-hydroxyphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]propanoate Chemical compound N1C2=NC=CN=C2C(CCC(=O)OCC)=C1C1=CC=C(O)C=C1 KUMRTJNGPLSWHP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims description 2
- 125000004247 indolizin-1-yl group Chemical group [H]C1=C([H])C(*)=C2C([H])=C([H])C([H])=C([H])N12 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- KCBDEKXPSQVLEP-UHFFFAOYSA-N methyl 2-[[2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetyl]amino]-3-methylpentanoate Chemical compound C12=CC(OC)=CC=C2N(CC(=O)NC(C(C)CC)C(=O)OC)C=C1C1=CC2=CC=CN=C2N1 KCBDEKXPSQVLEP-UHFFFAOYSA-N 0.000 claims description 2
- NUWVHJZFJTVFFF-UHFFFAOYSA-N n-(1-adamantyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NC45CC6CC(CC(C6)C4)C5)C4=CC=C(C=C43)OC)=CC2=C1 NUWVHJZFJTVFFF-UHFFFAOYSA-N 0.000 claims description 2
- DCXOOIFDLBTTMV-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC(CC1)CCN1CC1=CC=CC=C1 DCXOOIFDLBTTMV-UHFFFAOYSA-N 0.000 claims description 2
- GQMCFEHNSZEBAH-UHFFFAOYSA-N n-(1-benzylsulfanyl-3-hydroxypropan-2-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC(CO)CSCC1=CC=CC=C1 GQMCFEHNSZEBAH-UHFFFAOYSA-N 0.000 claims description 2
- APTYWMXFUGYVGM-UHFFFAOYSA-N n-(1-cyclohexylethyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC(C)C1CCCCC1 APTYWMXFUGYVGM-UHFFFAOYSA-N 0.000 claims description 2
- JGCBNDGUNFLGOT-UHFFFAOYSA-N n-(2-hydroxy-2-phenylethyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCC(O)C1=CC=CC=C1 JGCBNDGUNFLGOT-UHFFFAOYSA-N 0.000 claims description 2
- WCHHHXDNCZWUCN-UHFFFAOYSA-N n-(2-hydroxyethyl)-3-[5-methoxy-2-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propanamide Chemical compound C1=CN=C2NC(C=3N(CCC(=O)NCCO)C4=CC=C(C=C4C=3)OC)=CC2=C1 WCHHHXDNCZWUCN-UHFFFAOYSA-N 0.000 claims description 2
- VUISMYNHSHYGNC-UHFFFAOYSA-N n-(2-methoxyethyl)-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=C(OC)C=C2C(C=3NC=4N=CC=C(C=4C=3)C(=O)NCCOC)=CN(C)C2=C1 VUISMYNHSHYGNC-UHFFFAOYSA-N 0.000 claims description 2
- LYIYYGXAFXQMMY-UHFFFAOYSA-N n-(3,3-dimethylbutyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NCCC(C)(C)C)C4=CC=C(C=C43)OC)=CC2=C1 LYIYYGXAFXQMMY-UHFFFAOYSA-N 0.000 claims description 2
- RAQMCUQHYAXSAQ-UHFFFAOYSA-N n-(3-ethoxypropyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C12=CC(OC)=CC=C2N(CC(=O)NCCCOCC)C=C1C1=CC2=CC=CN=C2N1 RAQMCUQHYAXSAQ-UHFFFAOYSA-N 0.000 claims description 2
- XPWCAGOODXOSQF-UHFFFAOYSA-N n-(3-hydroxypropyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NCCCO)C4=CC=C(C=C43)OC)=CC2=C1 XPWCAGOODXOSQF-UHFFFAOYSA-N 0.000 claims description 2
- RUWBQGYDDYKZBO-UHFFFAOYSA-N n-(3-imidazol-1-ylpropyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCCN1C=CN=C1 RUWBQGYDDYKZBO-UHFFFAOYSA-N 0.000 claims description 2
- UAQOPUOGTVVJOG-UHFFFAOYSA-N n-(3-methoxyphenyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound COC1=CC=CC(NC(=O)CN2C3=CC=C(OC)C=C3C(C=3NC4=NC=CC=C4C=3)=C2)=C1 UAQOPUOGTVVJOG-UHFFFAOYSA-N 0.000 claims description 2
- BWDHNWLTLZYVPZ-UHFFFAOYSA-N n-(4-cyclohexylphenyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC(C=C1)=CC=C1C1CCCCC1 BWDHNWLTLZYVPZ-UHFFFAOYSA-N 0.000 claims description 2
- SDXMJIPVQXTKHA-UHFFFAOYSA-N n-(cyclohexylmethyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCC1CCCCC1 SDXMJIPVQXTKHA-UHFFFAOYSA-N 0.000 claims description 2
- BKYWCHNTPSJIPB-UHFFFAOYSA-N n-(furan-2-ylmethyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCC1=CC=CO1 BKYWCHNTPSJIPB-UHFFFAOYSA-N 0.000 claims description 2
- SNLRYUGDUCPNDC-UHFFFAOYSA-N n-(oxolan-2-ylmethyl)propanamide Chemical compound CCC(=O)NCC1CCCO1 SNLRYUGDUCPNDC-UHFFFAOYSA-N 0.000 claims description 2
- PFSVZOCOJUBWKM-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NCCC=4C5=CC=CC=C5NC=4)C4=CC=C(C=C43)OC)=CC2=C1 PFSVZOCOJUBWKM-UHFFFAOYSA-N 0.000 claims description 2
- OTLAWGHCSSWALL-UHFFFAOYSA-N n-[2-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-3-yl)ethyl]acetamide Chemical compound N1C2=NC=CC=C2C(CCNC(=O)C)=C1C1=CC=CC=C1 OTLAWGHCSSWALL-UHFFFAOYSA-N 0.000 claims description 2
- JITNVCCYVFHUPF-UHFFFAOYSA-N n-[2-(4-hydroxyphenyl)ethyl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCC1=CC=C(O)C=C1 JITNVCCYVFHUPF-UHFFFAOYSA-N 0.000 claims description 2
- UCEFCADDMARKNY-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-methylacetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)N(C)CCN(C)C)C4=CC=C(C=C43)OC)=CC2=C1 UCEFCADDMARKNY-UHFFFAOYSA-N 0.000 claims description 2
- BNUZXVCJKJCTDJ-UHFFFAOYSA-N n-[3-(4-methylpiperazin-1-yl)propyl]-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]acetamide Chemical compound C1CN(C)CCN1CCCNC(=O)CN1C(C=2NC3=NC=CC=C3C=2)=CC=C1 BNUZXVCJKJCTDJ-UHFFFAOYSA-N 0.000 claims description 2
- HBDRARBMLPCTGG-UHFFFAOYSA-N n-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCCCC=2C3=NC=CN=C3NC=2C=2C=CC(=CC=2)C(C)(C)C)=C1 HBDRARBMLPCTGG-UHFFFAOYSA-N 0.000 claims description 2
- JGMAAZXDUNJODZ-UHFFFAOYSA-N n-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propyl]cyclopropanecarboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=C(CCCNC(=O)C2CC2)C2=NC=CN=C2N1 JGMAAZXDUNJODZ-UHFFFAOYSA-N 0.000 claims description 2
- FVDAMNUVJJJNSL-UHFFFAOYSA-N n-benzyl-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-methylacetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(C)CC1=CC=CC=C1 FVDAMNUVJJJNSL-UHFFFAOYSA-N 0.000 claims description 2
- BDXRRHMLJWUPEC-UHFFFAOYSA-N n-benzyl-n-(2-hydroxyethyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CCO)CC1=CC=CC=C1 BDXRRHMLJWUPEC-UHFFFAOYSA-N 0.000 claims description 2
- JEFZUFURTMXHJS-UHFFFAOYSA-N n-cyclobutyl-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC1CCC1 JEFZUFURTMXHJS-UHFFFAOYSA-N 0.000 claims description 2
- UGAWDKCMHODVKI-UHFFFAOYSA-N n-cyclohexyl-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC1CCCCC1 UGAWDKCMHODVKI-UHFFFAOYSA-N 0.000 claims description 2
- PQQLLFPXCAFOIK-UHFFFAOYSA-N n-cyclopentyl-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC1CCCC1 PQQLLFPXCAFOIK-UHFFFAOYSA-N 0.000 claims description 2
- AHOFWEBRHKZIDP-UHFFFAOYSA-N n-cyclopropyl-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC1CC1 AHOFWEBRHKZIDP-UHFFFAOYSA-N 0.000 claims description 2
- FONFOCGAFSGSEP-UHFFFAOYSA-N n-isoquinolin-1-yl-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NC=4C5=CC=CC=C5C=CN=4)C4=CC=C(C=C43)OC)=CC2=C1 FONFOCGAFSGSEP-UHFFFAOYSA-N 0.000 claims description 2
- UVNXCLKSJRVXIO-UHFFFAOYSA-N n-isoquinolin-5-yl-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NC=4C5=CC=NC=C5C=CC=4)C4=CC=C(C=C43)OC)=CC2=C1 UVNXCLKSJRVXIO-UHFFFAOYSA-N 0.000 claims description 2
- LWNOUSJECJEDNF-UHFFFAOYSA-N n-methyl-3-[6-(4-morpholin-4-ylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propanamide Chemical compound N1C2=NC=CN=C2C(CCC(=O)NC)=C1C(C=C1)=CC=C1N1CCOCC1 LWNOUSJECJEDNF-UHFFFAOYSA-N 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 230000001668 ameliorated effect Effects 0.000 claims 10
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 2
- BFYPUSFBRCXJFG-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]ethanone Chemical compound C1CN(C(=O)CN2C(=CC=C2)C=2NC3=NC=CC=C3C=2)CCC1(O)C1=CC=C(Cl)C=C1 BFYPUSFBRCXJFG-UHFFFAOYSA-N 0.000 claims 1
- IURSYUWVAYZMLX-UHFFFAOYSA-N 2-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-3-yl)acetamide Chemical compound N1C2=NC=CC=C2C(CC(=O)N)=C1C1=CC=CC=C1 IURSYUWVAYZMLX-UHFFFAOYSA-N 0.000 claims 1
- SHISXEDJQZVJAL-UHFFFAOYSA-N 2-(4-methoxyphenyl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(OC)=CC=C1C1=CC2=CC=CN=C2N1 SHISXEDJQZVJAL-UHFFFAOYSA-N 0.000 claims 1
- UNQRREMUTOUZSE-UHFFFAOYSA-N 2-(4-methoxyphenyl)-3-methyl-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(OC)=CC=C1C1=C(C)C2=CC=CN=C2N1 UNQRREMUTOUZSE-UHFFFAOYSA-N 0.000 claims 1
- LYNAZMGLZOUVDV-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-quinolin-2-ylacetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NC=4N=C5C=CC=CC5=CC=4)C4=CC=C(C=C43)OC)=CC2=C1 LYNAZMGLZOUVDV-UHFFFAOYSA-N 0.000 claims 1
- SSYNYIMWLZUVAP-UHFFFAOYSA-N 3,5-dimethyl-4-[4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]-1,2-oxazole Chemical compound CC1=NOC(C)=C1C1=CC=C(C=2NC3=NC=CN=C3C=2)C=C1 SSYNYIMWLZUVAP-UHFFFAOYSA-N 0.000 claims 1
- MMWCUAAXINWETB-UHFFFAOYSA-N 3-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propyl]-1,1-diethylurea Chemical compound N1C2=NC=CN=C2C(CCCNC(=O)N(CC)CC)=C1C1=CC=C(C(C)(C)C)C=C1 MMWCUAAXINWETB-UHFFFAOYSA-N 0.000 claims 1
- HLUPMPDGNNAHRZ-UHFFFAOYSA-N 4-[2-[4-[4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]piperazin-1-yl]ethyl]morpholine Chemical compound C1CN(C=2C=CC(=CC=2)C=2NC3=NC=CN=C3C=2)CCN1CCN1CCOCC1 HLUPMPDGNNAHRZ-UHFFFAOYSA-N 0.000 claims 1
- ZKAWDAWXSOGKLM-UHFFFAOYSA-N 4-[2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetyl]piperazin-2-one Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCNC(=O)C1 ZKAWDAWXSOGKLM-UHFFFAOYSA-N 0.000 claims 1
- QYJOXPGTOAYSBH-UHFFFAOYSA-N 6-(1-methyl-5-phenylpyrrol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound CN1C=C(C=2NC3=NC=CN=C3C=2)C=C1C1=CC=CC=C1 QYJOXPGTOAYSBH-UHFFFAOYSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010047124 Vasculitis necrotising Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- OKGPJXPNOFADAQ-UHFFFAOYSA-N methyl 3-[[2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]amino]benzoate Chemical compound COC(=O)C1=CC=CC(NC=2C=3C=C(NC=3N=CC=2)C=2C3=CC(OC)=CC=C3N(C)C=2)=C1 OKGPJXPNOFADAQ-UHFFFAOYSA-N 0.000 claims 1
- FXURAMRMAPFYLX-UHFFFAOYSA-N n-(2-methoxyethyl)pyridine-4-carboxamide Chemical compound COCCNC(=O)C1=CC=NC=C1 FXURAMRMAPFYLX-UHFFFAOYSA-N 0.000 claims 1
- VFFVWJYTTADYPM-UHFFFAOYSA-N n-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propyl]butanamide Chemical compound N1C2=NC=CN=C2C(CCCNC(=O)CCC)=C1C1=CC=C(C(C)(C)C)C=C1 VFFVWJYTTADYPM-UHFFFAOYSA-N 0.000 claims 1
- PLWAKFARFCNHJO-UHFFFAOYSA-N n-methylpyridine-4-carboxamide Chemical compound CNC(=O)C1=CC=NC=C1 PLWAKFARFCNHJO-UHFFFAOYSA-N 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 201000005404 rubella Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 9
- 102000020233 phosphotransferase Human genes 0.000 abstract description 9
- 239000007787 solid Substances 0.000 description 222
- 239000000047 product Substances 0.000 description 199
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 117
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 99
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 76
- 239000000243 solution Substances 0.000 description 71
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 66
- 230000000875 corresponding effect Effects 0.000 description 55
- 238000002360 preparation method Methods 0.000 description 54
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 51
- 238000006243 chemical reaction Methods 0.000 description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- 238000004128 high performance liquid chromatography Methods 0.000 description 43
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 38
- 239000012442 inert solvent Substances 0.000 description 37
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- 238000005481 NMR spectroscopy Methods 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 28
- 239000011541 reaction mixture Substances 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 25
- 150000004677 hydrates Chemical class 0.000 description 25
- 150000001721 carbon Chemical group 0.000 description 24
- 238000010992 reflux Methods 0.000 description 21
- 239000002585 base Substances 0.000 description 19
- 238000011282 treatment Methods 0.000 description 19
- 239000012634 fragment Substances 0.000 description 18
- 238000003756 stirring Methods 0.000 description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 15
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 14
- 239000000377 silicon dioxide Substances 0.000 description 14
- 238000004809 thin layer chromatography Methods 0.000 description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 13
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 13
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 13
- 238000000921 elemental analysis Methods 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 11
- 125000004104 aryloxy group Chemical group 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- NUKAUWIUEJFXDV-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine-4-carbonitrile Chemical compound C12=CC(OC)=CC=C2NC=C1C1=CC2=C(C#N)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 NUKAUWIUEJFXDV-UHFFFAOYSA-N 0.000 description 10
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 10
- 102000004584 Somatomedin Receptors Human genes 0.000 description 10
- 108010017622 Somatomedin Receptors Proteins 0.000 description 10
- 230000029936 alkylation Effects 0.000 description 10
- 238000005804 alkylation reaction Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000012458 free base Substances 0.000 description 10
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- 102000001253 Protein Kinase Human genes 0.000 description 9
- 230000006978 adaptation Effects 0.000 description 9
- 229910052796 boron Inorganic materials 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 239000013066 combination product Substances 0.000 description 9
- 229940127555 combination product Drugs 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 9
- 108060006633 protein kinase Proteins 0.000 description 9
- 239000003643 water by type Substances 0.000 description 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 6
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- KVFIJIWMDBAGDP-UHFFFAOYSA-N ethylpyrazine Chemical compound CCC1=CN=CC=N1 KVFIJIWMDBAGDP-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 229960004063 propylene glycol Drugs 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- NWCNXQNJIZEBTG-UHFFFAOYSA-N 3-[6-(4-hydroxyphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]propanoic acid Chemical compound N1C2=NC=CN=C2C(CCC(=O)O)=C1C1=CC=C(O)C=C1 NWCNXQNJIZEBTG-UHFFFAOYSA-N 0.000 description 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 125000005553 heteroaryloxy group Chemical group 0.000 description 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000012280 lithium aluminium hydride Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 235000013772 propylene glycol Nutrition 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 5
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 4
- OONRFRRMUYCEEB-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-2-(1-methyl-5-pyridin-4-ylindol-3-yl)pyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1C1=CN(C)C2=CC=C(C=3C=CN=CC=3)C=C12 OONRFRRMUYCEEB-UHFFFAOYSA-N 0.000 description 4
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 239000004146 Propane-1,2-diol Substances 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000003435 aroyl group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- RSDOASZYYCOXIB-UHFFFAOYSA-N beta-alaninamide Chemical compound NCCC(N)=O RSDOASZYYCOXIB-UHFFFAOYSA-N 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000009510 drug design Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- IENZCGNHSIMFJE-UHFFFAOYSA-N indole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC=CC2=C1 IENZCGNHSIMFJE-UHFFFAOYSA-N 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 4
- 108010044426 integrins Proteins 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- BBHXAEXXTCXRHL-UHFFFAOYSA-N 2-[1-methyl-5-(1-methyltetrazol-5-yl)indol-3-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound CN1N=NN=C1C1=CC=C(N(C)C=C2C=3NC4=NC=CC=C4C=3)C2=C1 BBHXAEXXTCXRHL-UHFFFAOYSA-N 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- LMHHYPOKWRDJTP-UHFFFAOYSA-N 4-chloro-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1Cl LMHHYPOKWRDJTP-UHFFFAOYSA-N 0.000 description 3
- MWOCLUCRSVBPPP-UHFFFAOYSA-N 4-methoxy-2-(5-methoxy-1h-indol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2NC=C1C1=CC2=C(OC)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 MWOCLUCRSVBPPP-UHFFFAOYSA-N 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- IIZURLNRIMKEDL-UHFFFAOYSA-N 4-tert-butylbenzonitrile Chemical compound CC(C)(C)C1=CC=C(C#N)C=C1 IIZURLNRIMKEDL-UHFFFAOYSA-N 0.000 description 3
- HRMXBNUSPZDBGZ-UHFFFAOYSA-N 6-pyridin-4-yl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C=C1C1=CC=NC=C1 HRMXBNUSPZDBGZ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108091008875 B cell receptors Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010016672 Syk Kinase Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 description 3
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 3
- 150000008046 alkali metal hydrides Chemical class 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000024321 chromosome segregation Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000026045 iodination Effects 0.000 description 3
- 238000006192 iodination reaction Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- JKVRTUCVPZTEQZ-UHFFFAOYSA-N tributyltin azide Chemical compound CCCC[Sn](CCCC)(CCCC)N=[N+]=[N-] JKVRTUCVPZTEQZ-UHFFFAOYSA-N 0.000 description 3
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
- SDDGDIPSSYMLOY-UHFFFAOYSA-N 1-methyl-4-phenylpyrrole-3-carbonitrile Chemical compound CN1C=C(C#N)C(C=2C=CC=CC=2)=C1 SDDGDIPSSYMLOY-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- LCZUOKDVTBMCMX-UHFFFAOYSA-N 2,5-Dimethylpyrazine Chemical compound CC1=CN=C(C)C=N1 LCZUOKDVTBMCMX-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- 239000001934 2,5-dimethylpyrazine Substances 0.000 description 2
- HJFZAYHYIWGLNL-UHFFFAOYSA-N 2,6-Dimethylpyrazine Chemical compound CC1=CN=CC(C)=N1 HJFZAYHYIWGLNL-UHFFFAOYSA-N 0.000 description 2
- IAFLZDODMZVUGY-UHFFFAOYSA-N 2-(5,6-dimethoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CN=C2NC(C=3C=4C=C(C(=CC=4N(C)C=3)OC)OC)=CC2=C1 IAFLZDODMZVUGY-UHFFFAOYSA-N 0.000 description 2
- LPOOZQNTAHNETD-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-4-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2C1=CC=CC=C1 LPOOZQNTAHNETD-UHFFFAOYSA-N 0.000 description 2
- RCDWHRTWJKHQPB-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-5-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=2)=CC1=CC=2C1=CC=CC=C1 RCDWHRTWJKHQPB-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 2
- FURHRJBOFNDYTG-UHFFFAOYSA-N 2-fluoroethanamine Chemical compound NCCF FURHRJBOFNDYTG-UHFFFAOYSA-N 0.000 description 2
- OWISXYQFTOYGRO-UHFFFAOYSA-N 3,4-dimethylbenzonitrile Chemical compound CC1=CC=C(C#N)C=C1C OWISXYQFTOYGRO-UHFFFAOYSA-N 0.000 description 2
- ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- QNNURFLOTYFVLC-UHFFFAOYSA-N 4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)benzaldehyde;hydrate Chemical compound O.C1=CC(C=O)=CC=C1C1=CC2=NC=CN=C2N1 QNNURFLOTYFVLC-UHFFFAOYSA-N 0.000 description 2
- YBAZINRZQSAIAY-UHFFFAOYSA-N 4-aminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1 YBAZINRZQSAIAY-UHFFFAOYSA-N 0.000 description 2
- JFFMPLDYSOUBPW-UHFFFAOYSA-N 4-methoxy-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1OC JFFMPLDYSOUBPW-UHFFFAOYSA-N 0.000 description 2
- REGLPYFBVKECSK-UHFFFAOYSA-N 6-(1,4-dimethylpyrrol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound CC1=CN(C)C=C1C1=CC2=NC=CN=C2N1 REGLPYFBVKECSK-UHFFFAOYSA-N 0.000 description 2
- 102100035634 B-cell linker protein Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010057254 Connective tissue inflammation Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 2
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000000551 Syk Kinase Human genes 0.000 description 2
- 235000004338 Syringa vulgaris Nutrition 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 125000005239 aroylamino group Chemical group 0.000 description 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 239000003245 coal Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000005828 desilylation reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 2
- QBOSBMXRDFSANN-UHFFFAOYSA-N ethyl 2-[1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-5-yl]oxyacetate Chemical compound C12=CC(OCC(=O)OCC)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 QBOSBMXRDFSANN-UHFFFAOYSA-N 0.000 description 2
- SMVBADCAMQOTOV-UHFFFAOYSA-N ethyl cyclobutanecarboxylate Chemical class CCOC(=O)C1CCC1 SMVBADCAMQOTOV-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 150000003903 lactic acid esters Chemical class 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 description 2
- 150000002690 malonic acid derivatives Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- HMSLTGXEUDAMOE-UHFFFAOYSA-N methanesulfonic acid;2-[5-methoxy-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]-1-morpholin-4-ylethanone Chemical compound CS(O)(=O)=O.C1=C(C=2NC3=NC=CN=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCOCC1 HMSLTGXEUDAMOE-UHFFFAOYSA-N 0.000 description 2
- SEGAYCRVQDVTNC-UHFFFAOYSA-N methanesulfonic acid;6-(5-methoxy-1-methylindol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound CS(O)(=O)=O.C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=N1 SEGAYCRVQDVTNC-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 2
- CAWHJQAVHZEVTJ-UHFFFAOYSA-N methylpyrazine Chemical compound CC1=CN=CC=N1 CAWHJQAVHZEVTJ-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- QLWVZFKXLGZRBW-UHFFFAOYSA-N n-(1-hydroxy-2-methylpropan-2-yl)-1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C12=CC(C(=O)NC(C)(C)CO)=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 QLWVZFKXLGZRBW-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- 150000003901 oxalic acid esters Chemical class 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 150000004965 peroxy acids Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000003909 protein kinase inhibitor Substances 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003902 salicylic acid esters Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000003900 succinic acid esters Chemical class 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 150000003899 tartaric acid esters Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- FZRRMJVEUXGESA-UHFFFAOYSA-N trimethyl-[2-[[3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]methoxy]ethyl]silane Chemical compound C12=CC=CC=C2N(COCC[Si](C)(C)C)C=C1C1=CC2=NC=CN=C2N1 FZRRMJVEUXGESA-UHFFFAOYSA-N 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- SKZATSYUNIDNIP-LJQANCHMSA-N (2r)-3-[1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-5-yl]oxypropane-1,2-diol Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1C1=CN(C)C2=CC=C(OC[C@H](O)CO)C=C12 SKZATSYUNIDNIP-LJQANCHMSA-N 0.000 description 1
- KCDTXLZHKMXLND-LJQANCHMSA-N (2r)-3-[6-methoxy-1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-5-yl]oxypropane-1,2-diol Chemical compound C1=2C=C(OC[C@H](O)CO)C(OC)=CC=2N(C)C=C1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 KCDTXLZHKMXLND-LJQANCHMSA-N 0.000 description 1
- GCUYYSTWKXFOPG-UHFFFAOYSA-N (3,5-dimethyl-2h-1,3-oxazol-4-yl)boronic acid Chemical compound CN1COC(C)=C1B(O)O GCUYYSTWKXFOPG-UHFFFAOYSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- ABFQGXBZQWZNKI-UHFFFAOYSA-N 1,1-dimethoxyethanol Chemical compound COC(C)(O)OC ABFQGXBZQWZNKI-UHFFFAOYSA-N 0.000 description 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 150000000183 1,3-benzoxazoles Chemical class 0.000 description 1
- CREIBTJGSHDKBR-UHFFFAOYSA-N 1,3-dimethyl-2-phenylpyrrolo[2,3-b]pyridine Chemical compound CN1C2=NC=CC=C2C(C)=C1C1=CC=CC=C1 CREIBTJGSHDKBR-UHFFFAOYSA-N 0.000 description 1
- JCQGMSHWWIIMLE-UHFFFAOYSA-N 1,4-dimethylpyrrole-3-carbonitrile Chemical compound CC1=CN(C)C=C1C#N JCQGMSHWWIIMLE-UHFFFAOYSA-N 0.000 description 1
- SMEUSSLSLVISEV-UHFFFAOYSA-N 1,5-dimethylpyrrole-3-carbonitrile Chemical compound CC1=CC(C#N)=CN1C SMEUSSLSLVISEV-UHFFFAOYSA-N 0.000 description 1
- WZVHBNGMCBANPQ-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-2-(1-methylpyrrol-2-yl)pyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1C1=CC=CN1C WZVHBNGMCBANPQ-UHFFFAOYSA-N 0.000 description 1
- ZCPVXUJWWDIBHV-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-2-(1h-pyrrol-2-yl)pyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1C1=CC=CN1 ZCPVXUJWWDIBHV-UHFFFAOYSA-N 0.000 description 1
- NSNZZTVUYQKEMX-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1 NSNZZTVUYQKEMX-UHFFFAOYSA-N 0.000 description 1
- TUZBJTRDNQFMOT-UHFFFAOYSA-N 1-[1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-5-yl]oxypropan-2-ol Chemical compound C12=CC(OCC(O)C)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 TUZBJTRDNQFMOT-UHFFFAOYSA-N 0.000 description 1
- CYSYOXMYZXJMHB-UHFFFAOYSA-N 1-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propyl]-3-propylurea Chemical compound N1C2=NC=CN=C2C(CCCNC(=O)NCCC)=C1C1=CC=C(C(C)(C)C)C=C1 CYSYOXMYZXJMHB-UHFFFAOYSA-N 0.000 description 1
- ADBXIRDSZMZSTN-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)piperazin-1-yl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCN1C1=CC=C(Cl)C=C1 ADBXIRDSZMZSTN-UHFFFAOYSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- AHRLDZHURASTFL-UHFFFAOYSA-N 1-benzyl-5-methoxyindole-3-carbonitrile Chemical compound C1=C(C#N)C2=CC(OC)=CC=C2N1CC1=CC=CC=C1 AHRLDZHURASTFL-UHFFFAOYSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- OQURWGJAWSLGQG-UHFFFAOYSA-N 1-isocyanatopropane Chemical compound CCCN=C=O OQURWGJAWSLGQG-UHFFFAOYSA-N 0.000 description 1
- SIZVCQPCIHCEFE-UHFFFAOYSA-N 1-methyl-2-phenylpyrrole-3-carbonitrile Chemical compound CN1C=CC(C#N)=C1C1=CC=CC=C1 SIZVCQPCIHCEFE-UHFFFAOYSA-N 0.000 description 1
- ORAALBRTYXFNGK-UHFFFAOYSA-N 1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-5-ol Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1C1=CN(C)C2=CC=C(O)C=C12 ORAALBRTYXFNGK-UHFFFAOYSA-N 0.000 description 1
- CTVJCXXBSZEUHR-UHFFFAOYSA-N 1-methyl-5-phenylpyrazole-3-carbonitrile Chemical compound CN1N=C(C#N)C=C1C1=CC=CC=C1 CTVJCXXBSZEUHR-UHFFFAOYSA-N 0.000 description 1
- AMDSSWGEPMPSIT-UHFFFAOYSA-N 1-methyl-5-phenylpyrrole-3-carbonitrile Chemical compound CN1C=C(C#N)C=C1C1=CC=CC=C1 AMDSSWGEPMPSIT-UHFFFAOYSA-N 0.000 description 1
- FBAXZPMXGBNBPE-UHFFFAOYSA-N 1-methylindole-3-carbonitrile Chemical compound C1=CC=C2N(C)C=C(C#N)C2=C1 FBAXZPMXGBNBPE-UHFFFAOYSA-N 0.000 description 1
- DYZZFEHAJOLDEX-UHFFFAOYSA-N 1-methylindole-5-carbonitrile Chemical compound N#CC1=CC=C2N(C)C=CC2=C1 DYZZFEHAJOLDEX-UHFFFAOYSA-N 0.000 description 1
- UHQAIJFIXCOBCN-UHFFFAOYSA-N 1-methylindole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N(C)C=CC2=C1 UHQAIJFIXCOBCN-UHFFFAOYSA-N 0.000 description 1
- NIBQNKBEGIMBSV-UHFFFAOYSA-N 1-methylpyrazole-4-carbonitrile Chemical compound CN1C=C(C#N)C=N1 NIBQNKBEGIMBSV-UHFFFAOYSA-N 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- GHTDODSYDCPOCW-UHFFFAOYSA-N 1h-indole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C=CNC2=C1 GHTDODSYDCPOCW-UHFFFAOYSA-N 0.000 description 1
- VOUFNWHPFTVAMY-UHFFFAOYSA-N 2-(1,3-dioxan-2-yl)benzonitrile Chemical compound C(#N)C1=C(C=CC=C1)C1OCCCO1 VOUFNWHPFTVAMY-UHFFFAOYSA-N 0.000 description 1
- YAIMUUJMEBJXAA-UHFFFAOYSA-N 2-(2-methylpropyl)pyrazine Chemical compound CC(C)CC1=CN=CC=N1 YAIMUUJMEBJXAA-UHFFFAOYSA-N 0.000 description 1
- JRGNVEQMRMUETH-UHFFFAOYSA-N 2-(4-tert-butylphenyl)-4-chloro-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC(Cl)=C2C=C1C1=CC=C(C(C)(C)C)C=C1 JRGNVEQMRMUETH-UHFFFAOYSA-N 0.000 description 1
- JZSAWHOFIOPYNV-UHFFFAOYSA-N 2-(5-methoxy-1-methyl-6-propan-2-yloxyindol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C=1N(C)C=2C=C(OC(C)C)C(OC)=CC=2C=1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 JZSAWHOFIOPYNV-UHFFFAOYSA-N 0.000 description 1
- PMPACJBHNPDHAR-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-1-(4-methylphenyl)sulfonyl-4-phenylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C1=CC2=C(C=3C=CC=CC=3)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 PMPACJBHNPDHAR-UHFFFAOYSA-N 0.000 description 1
- PJUXIMOZNKTDQG-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-1-(4-methylphenyl)sulfonyl-5-phenylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C1=CC2=CC(C=3C=CC=CC=3)=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 PJUXIMOZNKTDQG-UHFFFAOYSA-N 0.000 description 1
- MRZAFOHXWPRVPQ-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 MRZAFOHXWPRVPQ-UHFFFAOYSA-N 0.000 description 1
- XCLJFTFBHKDRHP-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxylic acid Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1C(O)=O XCLJFTFBHKDRHP-UHFFFAOYSA-N 0.000 description 1
- CBFKLVAQWIOSOV-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-3-methyl-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C1=C(C)C2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 CBFKLVAQWIOSOV-UHFFFAOYSA-N 0.000 description 1
- ZVEJOVUCQDIHIC-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-3-methyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C(C)=C1C1=CN(C)C2=CC=C(OC)C=C21 ZVEJOVUCQDIHIC-UHFFFAOYSA-N 0.000 description 1
- DIJJUHWPCLPQPG-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-n-[(4-methoxyphenyl)methyl]-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C1=CC(OC)=CC=C1CNC1=CC=NC2=C1C=C(C=1C3=CC(OC)=CC=C3N(C)C=1)N2 DIJJUHWPCLPQPG-UHFFFAOYSA-N 0.000 description 1
- NTXNTJKCZGSAKO-UHFFFAOYSA-N 2-(6-phenyl-5h-pyrrolo[2,3-b]pyrazin-7-yl)acetic acid Chemical compound N1C2=NC=CN=C2C(CC(=O)O)=C1C1=CC=CC=C1 NTXNTJKCZGSAKO-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- IDCHTBKPGIHRSA-UHFFFAOYSA-N 2-[5-(1-methoxypropan-2-yloxy)-1-methylindol-3-yl]-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC(C)COC)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 IDCHTBKPGIHRSA-UHFFFAOYSA-N 0.000 description 1
- UDCRMLPEZMWHKH-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(3-methylbutyl)acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NCCC(C)C)C4=CC=C(C=C43)OC)=CC2=C1 UDCRMLPEZMWHKH-UHFFFAOYSA-N 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- VTXWAVDGZZPPIO-UHFFFAOYSA-N 2-but-3-enylpyrazine Chemical compound C=CCCC1=CN=CC=N1 VTXWAVDGZZPPIO-UHFFFAOYSA-N 0.000 description 1
- YMQRPXBBBOXHNZ-UHFFFAOYSA-N 2-chloro-1-morpholin-4-ylethanone Chemical compound ClCC(=O)N1CCOCC1 YMQRPXBBBOXHNZ-UHFFFAOYSA-N 0.000 description 1
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- ZSMJMLCFRNJKJN-UHFFFAOYSA-N 2-iodo-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine-4-carbonitrile Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC(C#N)=C2C=C1I ZSMJMLCFRNJKJN-UHFFFAOYSA-N 0.000 description 1
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- BEVMNJLOWZOCEF-UHFFFAOYSA-N 2-methyl-6-phenyl-5h-pyrrolo[2,3-b]pyrazine Chemical compound C=1C2=NC(C)=CN=C2NC=1C1=CC=CC=C1 BEVMNJLOWZOCEF-UHFFFAOYSA-N 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- IBPDDHRIVGDVHF-UHFFFAOYSA-N 2-prop-1-enyl-5H-pyrrolo[2,3-b]pyrazine Chemical compound C(=CC)C=1N=C2C(=NC=1)NC=C2 IBPDDHRIVGDVHF-UHFFFAOYSA-N 0.000 description 1
- HVLUYXIJZLDNIS-UHFFFAOYSA-N 2-thiophen-2-ylethanamine Chemical compound NCCC1=CC=CS1 HVLUYXIJZLDNIS-UHFFFAOYSA-N 0.000 description 1
- OSEQIDSFSBWXRE-UHFFFAOYSA-N 3,4-dimethoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1OC OSEQIDSFSBWXRE-UHFFFAOYSA-N 0.000 description 1
- AMEPOOHICAMGGM-UHFFFAOYSA-N 3-(1,3-dioxan-2-yl)benzonitrile Chemical compound N#CC1=CC=CC(C2OCCCO2)=C1 AMEPOOHICAMGGM-UHFFFAOYSA-N 0.000 description 1
- BYVKEXFULGWIKG-UHFFFAOYSA-N 3-(4-cyano-1h-pyrrolo[2,3-b]pyridin-2-yl)-n-(1-hydroxy-2-methylpropan-2-yl)-1-methylindole-5-carboxamide Chemical class C12=CC(C(=O)NC(C)(C)CO)=CC=C2N(C)C=C1C1=CC2=C(C#N)C=CN=C2N1 BYVKEXFULGWIKG-UHFFFAOYSA-N 0.000 description 1
- JACOAARTFSSSMB-UHFFFAOYSA-N 3-[1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-5-yl]oxypropan-1-ol Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1C1=CN(C)C2=CC=C(OCCCO)C=C12 JACOAARTFSSSMB-UHFFFAOYSA-N 0.000 description 1
- SKZATSYUNIDNIP-UHFFFAOYSA-N 3-[1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-5-yl]oxypropane-1,2-diol Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1C1=CN(C)C2=CC=C(OCC(O)CO)C=C12 SKZATSYUNIDNIP-UHFFFAOYSA-N 0.000 description 1
- AQBXUKJULHZLDI-UHFFFAOYSA-N 3-[6-(4-hydroxyphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]propanamide Chemical compound N1C2=NC=CN=C2C(CCC(=O)N)=C1C1=CC=C(O)C=C1 AQBXUKJULHZLDI-UHFFFAOYSA-N 0.000 description 1
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 description 1
- PDLNHDSYGLTYDS-UHFFFAOYSA-N 3-aminopropanoic acid;hydrochloride Chemical compound Cl.NCCC(O)=O PDLNHDSYGLTYDS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- STXAVEHFKAXGOX-UHFFFAOYSA-N 3-bromobenzonitrile Chemical compound BrC1=CC=CC(C#N)=C1 STXAVEHFKAXGOX-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- KLXSUMLEPNAZFK-UHFFFAOYSA-N 3-methoxybenzonitrile Chemical compound COC1=CC=CC(C#N)=C1 KLXSUMLEPNAZFK-UHFFFAOYSA-N 0.000 description 1
- PKZDPOGLGBWEGP-UHFFFAOYSA-N 3-methyl-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC=C2C(C)=CNC2=N1 PKZDPOGLGBWEGP-UHFFFAOYSA-N 0.000 description 1
- UPAYIGZHWMYXCV-UHFFFAOYSA-N 3-methyl-2-(4-methylphenyl)-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C(C)=C1C1=CC=C(C)C=C1 UPAYIGZHWMYXCV-UHFFFAOYSA-N 0.000 description 1
- UGBJLTPTFVECSC-UHFFFAOYSA-N 3-methyl-2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C(C)=C1C1=CC=CC=C1 UGBJLTPTFVECSC-UHFFFAOYSA-N 0.000 description 1
- YCQRBNHIBAGRDM-UHFFFAOYSA-N 3-methylindolizine-1-carbonitrile Chemical compound C1=CC=CN2C(C)=CC(C#N)=C21 YCQRBNHIBAGRDM-UHFFFAOYSA-N 0.000 description 1
- XWHIXOMWXCHJPP-UHFFFAOYSA-N 4-(trifluoromethoxy)benzonitrile Chemical compound FC(F)(F)OC1=CC=C(C#N)C=C1 XWHIXOMWXCHJPP-UHFFFAOYSA-N 0.000 description 1
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical class O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 1
- HQSCPPCMBMFJJN-UHFFFAOYSA-N 4-bromobenzonitrile Chemical compound BrC1=CC=C(C#N)C=C1 HQSCPPCMBMFJJN-UHFFFAOYSA-N 0.000 description 1
- HYHQFHGGYUZYKX-UHFFFAOYSA-N 4-chloro-2-(5-methoxy-1-methylindol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C1=CC2=C(Cl)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 HYHQFHGGYUZYKX-UHFFFAOYSA-N 0.000 description 1
- CVNOWLNNPYYEOH-UHFFFAOYSA-N 4-cyanophenol Chemical compound OC1=CC=C(C#N)C=C1 CVNOWLNNPYYEOH-UHFFFAOYSA-N 0.000 description 1
- TYXWDMWSFQYDKQ-UHFFFAOYSA-N 4-diphenylphosphanylbutan-2-yl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)C(C)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 TYXWDMWSFQYDKQ-UHFFFAOYSA-N 0.000 description 1
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- RSGFDIWQURPTQL-UHFFFAOYSA-N 4-methoxy-2-(5-methoxy-1-methylindol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C1=CC2=C(OC)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 RSGFDIWQURPTQL-UHFFFAOYSA-N 0.000 description 1
- XDJAAZYHCCRJOK-UHFFFAOYSA-N 4-methoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1 XDJAAZYHCCRJOK-UHFFFAOYSA-N 0.000 description 1
- RPVGEEHGKIFQFO-UHFFFAOYSA-N 4-methylsulfanylbenzonitrile Chemical compound CSC1=CC=C(C#N)C=C1 RPVGEEHGKIFQFO-UHFFFAOYSA-N 0.000 description 1
- CUTDHMHDGHQIED-UHFFFAOYSA-N 5,6,7,8-tetrahydroindolizine-1-carbonitrile Chemical compound C1CCCC2=C(C#N)C=CN21 CUTDHMHDGHQIED-UHFFFAOYSA-N 0.000 description 1
- FRWDASPBRXZPCF-UHFFFAOYSA-N 5-bromo-3-methyl-2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=C(Br)C=C2C(C)=C1C1=CC=CC=C1 FRWDASPBRXZPCF-UHFFFAOYSA-N 0.000 description 1
- VMIYBJLJAHMDLZ-UHFFFAOYSA-N 5-methoxy-1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-6-ol Chemical compound C=1N(C)C=2C=C(O)C(OC)=CC=2C=1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 VMIYBJLJAHMDLZ-UHFFFAOYSA-N 0.000 description 1
- OIPMMVPDCMQPEK-UHFFFAOYSA-N 5-methoxy-1-methylindole-3-carbonitrile Chemical compound COC1=CC=C2N(C)C=C(C#N)C2=C1 OIPMMVPDCMQPEK-UHFFFAOYSA-N 0.000 description 1
- HFTVJMFWJUFBNO-UHFFFAOYSA-N 5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC=CC2=N1 HFTVJMFWJUFBNO-UHFFFAOYSA-N 0.000 description 1
- INOGZQRUJJRLMW-UHFFFAOYSA-N 6-(1,5-dimethylpyrrol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound CN1C(C)=CC(C=2NC3=NC=CN=C3C=2)=C1 INOGZQRUJJRLMW-UHFFFAOYSA-N 0.000 description 1
- BYAZDVQHMGZBBN-UHFFFAOYSA-N 6-(1-methylpyrazol-4-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=NN(C)C=C1C1=CC2=NC=CN=C2N1 BYAZDVQHMGZBBN-UHFFFAOYSA-N 0.000 description 1
- VFKHBJJSGUYSDC-UHFFFAOYSA-N 6-(4-chlorophenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(Cl)=CC=C1C1=CC2=NC=CN=C2N1 VFKHBJJSGUYSDC-UHFFFAOYSA-N 0.000 description 1
- WCMRADNCDSUPBD-UHFFFAOYSA-N 6-(5-methoxy-1-methylindol-3-yl)-2-methyl-5h-pyrrolo[2,3-b]pyrazine Chemical compound CC1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=N1 WCMRADNCDSUPBD-UHFFFAOYSA-N 0.000 description 1
- FFKTVFFDFAAUHY-UHFFFAOYSA-N 6-(5-methoxy-1-methylindol-3-yl)-7-methyl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C(C)=C1C1=CN(C)C2=CC=C(OC)C=C21 FFKTVFFDFAAUHY-UHFFFAOYSA-N 0.000 description 1
- GXYKGJZXOCFTBB-UHFFFAOYSA-N 6-[1-(3-bromopropyl)indol-3-yl]-5h-pyrrolo[2,3-b]pyrazine Chemical compound C12=CC=CC=C2N(CCCBr)C=C1C1=CC2=NC=CN=C2N1 GXYKGJZXOCFTBB-UHFFFAOYSA-N 0.000 description 1
- NNXKRJSTOZGIFL-UHFFFAOYSA-N 6-methoxy-1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-5-ol Chemical compound C1=2C=C(O)C(OC)=CC=2N(C)C=C1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 NNXKRJSTOZGIFL-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000004000 Aurora Kinase A Human genes 0.000 description 1
- 101710083670 B-cell linker protein Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 241000596110 Biosteres Species 0.000 description 1
- NGWBSBOVOMDCOZ-UHFFFAOYSA-N CC(C(=O)O)(CC1=C(NC2=NC=CN=C21)C2=CC=C(C=C2)OC)C Chemical compound CC(C(=O)O)(CC1=C(NC2=NC=CN=C21)C2=CC=C(C=C2)OC)C NGWBSBOVOMDCOZ-UHFFFAOYSA-N 0.000 description 1
- 125000006519 CCH3 Chemical group 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- XDCYTBGOVFUNAC-UHFFFAOYSA-N CN1C2=CC=CC=C2C(C2=CC3=CC=CN=C3N2)=C1.NC(CO)(CO)CO Chemical compound CN1C2=CC=CC=C2C(C2=CC3=CC=CN=C3N2)=C1.NC(CO)(CO)CO XDCYTBGOVFUNAC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 241000255582 Drosophilidae Species 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 229940124783 FAK inhibitor Drugs 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000798300 Homo sapiens Aurora kinase A Proteins 0.000 description 1
- 101000803266 Homo sapiens B-cell linker protein Proteins 0.000 description 1
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 102100039897 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- UVPSSGJTBLNVRE-UHFFFAOYSA-N Moniliformin Natural products O=C1C(OC)=CC(=O)C=2C1=C1C(=O)C(OC)=CC(=O)C1=CC=2 UVPSSGJTBLNVRE-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- IAVCVKGRTKDDCM-UHFFFAOYSA-N N-(1-hydroxy-2-methylpropan-2-yl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide methanesulfonic acid Chemical compound CS(=O)(=O)O.OCC(C)(C)NC(=O)C=1C=C2C(=CN(C2=CC1)C)C1=CC=2C(=NC=CC2)N1 IAVCVKGRTKDDCM-UHFFFAOYSA-N 0.000 description 1
- NDCGVLJXFQKXOF-UHFFFAOYSA-N N-hydroxy-2-methylpropanamine Chemical compound CC(C)CNO NDCGVLJXFQKXOF-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- PBULLSLGEGXPEZ-UHFFFAOYSA-N N1(CCOCC1)CCNC(=O)C=1C=C2C(=CN(C2=CC1)C)C1=CC=2C(=NC=CC2)N1.NCCN1CCOCC1 Chemical compound N1(CCOCC1)CCNC(=O)C=1C=C2C(=CN(C2=CC1)C)C1=CC=2C(=NC=CC2)N1.NCCN1CCOCC1 PBULLSLGEGXPEZ-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- WWIQWRLUVCVLTJ-UHFFFAOYSA-N O1C=C(C=C1)C1=CC=2C(=NC=CN2)N1.O1C=C(C=C1)C#N Chemical compound O1C=C(C=C1)C1=CC=2C(=NC=CN2)N1.O1C=C(C=C1)C#N WWIQWRLUVCVLTJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 238000005874 Vilsmeier-Haack formylation reaction Methods 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- HWAUZBRXALUJMH-UHFFFAOYSA-N [N+]=1(C=CC2=CC=CNC=12)[O-] Chemical compound [N+]=1(C=CC2=CC=CNC=12)[O-] HWAUZBRXALUJMH-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- VNEMVKOXLBIWTB-UHFFFAOYSA-N aminomethyl benzoate Chemical class NCOC(=O)C1=CC=CC=C1 VNEMVKOXLBIWTB-UHFFFAOYSA-N 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000002152 aqueous-organic solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- ZWJMXJUZYGTMSZ-UHFFFAOYSA-N bis(2-methylbenzoyl) 2,3-dihydroxybutanedioate Chemical class CC1=CC=CC=C1C(=O)OC(=O)C(O)C(O)C(=O)OC(=O)C1=CC=CC=C1C ZWJMXJUZYGTMSZ-UHFFFAOYSA-N 0.000 description 1
- OGODKNYCTJYXFF-UHFFFAOYSA-N bis(4-methylbenzoyl) 2,3-dihydroxybutanedioate Chemical class C1=CC(C)=CC=C1C(=O)OC(=O)C(O)C(O)C(=O)OC(=O)C1=CC=C(C)C=C1 OGODKNYCTJYXFF-UHFFFAOYSA-N 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229930188620 butyrolactone Natural products 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- VHILMKFSCRWWIJ-UHFFFAOYSA-N dimethyl acetylenedicarboxylate Chemical compound COC(=O)C#CC(=O)OC VHILMKFSCRWWIJ-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- WGYNZBIFSWZNMA-UHFFFAOYSA-N dipropan-2-yl but-2-ynedioate Chemical compound CC(C)OC(=O)C#CC(=O)OC(C)C WGYNZBIFSWZNMA-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- FVJFRFUSHCIRKP-UHFFFAOYSA-N disodium;hydrogen borate Chemical compound [Na+].[Na+].OB([O-])[O-] FVJFRFUSHCIRKP-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000017793 embryonic organ development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- GDMNEKQQFQMIMP-UHFFFAOYSA-N ethyl 2-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propylcarbamoylamino]acetate Chemical compound N1C2=NC=CN=C2C(CCCNC(=O)NCC(=O)OCC)=C1C1=CC=C(C(C)(C)C)C=C1 GDMNEKQQFQMIMP-UHFFFAOYSA-N 0.000 description 1
- GGSZYSPQSNAXFZ-UHFFFAOYSA-N ethyl 2-[5-methoxy-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-1-yl]acetate Chemical compound C12=CC(OC)=CC=C2N(CC(=O)OCC)C=C1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 GGSZYSPQSNAXFZ-UHFFFAOYSA-N 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000002476 indolines Chemical class 0.000 description 1
- IKMSBSJONUMYEI-UHFFFAOYSA-N indolizine-1-carbonitrile Chemical compound C1=CC=CC2=C(C#N)C=CN21 IKMSBSJONUMYEI-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002083 iodinating effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- GXXBVBVNGMCFIU-UHFFFAOYSA-N isoquinoline-3-carbonitrile Chemical compound C1=CC=C2C=NC(C#N)=CC2=C1 GXXBVBVNGMCFIU-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NAIXDPFXVPAHKH-UHFFFAOYSA-N methanesulfonic acid;2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound CS(O)(=O)=O.C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1 NAIXDPFXVPAHKH-UHFFFAOYSA-N 0.000 description 1
- UAWBKMRSNQHKOA-UHFFFAOYSA-N methanesulfonic acid;2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-morpholin-4-ylethanone Chemical compound CS(O)(=O)=O.C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCOCC1 UAWBKMRSNQHKOA-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- NDBQJIBNNUJNHA-DFWYDOINSA-N methyl (2s)-2-amino-3-hydroxypropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CO NDBQJIBNNUJNHA-DFWYDOINSA-N 0.000 description 1
- OVYHABPMJWQIAZ-UHFFFAOYSA-N methyl 1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxylate Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)OC)=CC2=N1 OVYHABPMJWQIAZ-UHFFFAOYSA-N 0.000 description 1
- JWPYKMVUNLCFIN-UHFFFAOYSA-N methyl 6-[[2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetyl]amino]hexanoate Chemical compound C12=CC(OC)=CC=C2N(CC(=O)NCCCCCC(=O)OC)C=C1C1=CC2=CC=CN=C2N1 JWPYKMVUNLCFIN-UHFFFAOYSA-N 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- BDRTVPCFKSUHCJ-UHFFFAOYSA-N molecular hydrogen;potassium Chemical compound [K].[H][H] BDRTVPCFKSUHCJ-UHFFFAOYSA-N 0.000 description 1
- KGPQKNJSZNXOPV-UHFFFAOYSA-N moniliformin Chemical compound OC1=CC(=O)C1=O KGPQKNJSZNXOPV-UHFFFAOYSA-N 0.000 description 1
- GSENCEDSCQYPIL-UHFFFAOYSA-N morpholin-4-ylmethanone Chemical compound O=[C]N1CCOCC1 GSENCEDSCQYPIL-UHFFFAOYSA-N 0.000 description 1
- LPWAKYISHIZIPO-UHFFFAOYSA-N morpholin-4-ylmethyl benzoate Chemical class C=1C=CC=CC=1C(=O)OCN1CCOCC1 LPWAKYISHIZIPO-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- MBHINSULENHCMF-UHFFFAOYSA-N n,n-dimethylpropanamide Chemical compound CCC(=O)N(C)C MBHINSULENHCMF-UHFFFAOYSA-N 0.000 description 1
- ZZNPIMREDONCNL-UHFFFAOYSA-N n-(1-hydroxy-2-methylpropan-2-yl)-1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NC(C)(C)CO)=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 ZZNPIMREDONCNL-UHFFFAOYSA-N 0.000 description 1
- XZRYCTLOGNCQDG-UHFFFAOYSA-N n-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indole-5-carboxamide Chemical compound C12=CC(C(=O)NC(C)(C)CO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 XZRYCTLOGNCQDG-UHFFFAOYSA-N 0.000 description 1
- NQGBDQFBNJWTKV-UHFFFAOYSA-N n-(2-hydroxy-2-phenylethyl)-3-[5-methoxy-2-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propanamide Chemical compound C=1C2=CC=CN=C2NC=1C1=CC2=CC(OC)=CC=C2N1CCC(=O)NCC(O)C1=CC=CC=C1 NQGBDQFBNJWTKV-UHFFFAOYSA-N 0.000 description 1
- DCVMKOMYZCLPRK-UHFFFAOYSA-N n-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propyl]-2-methoxyacetamide Chemical compound N1C2=NC=CN=C2C(CCCNC(=O)COC)=C1C1=CC=C(C(C)(C)C)C=C1 DCVMKOMYZCLPRK-UHFFFAOYSA-N 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- OGDOBXMNVNGETJ-UHFFFAOYSA-N oxan-2-ylurea Chemical compound NC(=O)NC1CCCCO1 OGDOBXMNVNGETJ-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000005554 pyridyloxy group Chemical group 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- WDXARTMCIRVMAE-UHFFFAOYSA-N quinoline-2-carbonitrile Chemical compound C1=CC=CC2=NC(C#N)=CC=C21 WDXARTMCIRVMAE-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012363 selectfluor Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- BKEVUZHCAQICFT-UHFFFAOYSA-M sodium;1-formylpiperidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCCCN1C=O BKEVUZHCAQICFT-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- PMHVRQIEKSJLPW-UHFFFAOYSA-N tert-butyl n-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]carbamate Chemical compound C12=CC(NC(=O)OC(C)(C)C)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 PMHVRQIEKSJLPW-UHFFFAOYSA-N 0.000 description 1
- WMXCDAVJEZZYLT-UHFFFAOYSA-N tert-butylthiol Chemical compound CC(C)(C)S WMXCDAVJEZZYLT-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- VNNLHYZDXIBHKZ-UHFFFAOYSA-N thiophene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CS1 VNNLHYZDXIBHKZ-UHFFFAOYSA-N 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- LGQXXHMEBUOXRP-UHFFFAOYSA-N tributyl borate Chemical compound CCCCOB(OCCCC)OCCCC LGQXXHMEBUOXRP-UHFFFAOYSA-N 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- PXSQLMPCRDHKPE-UHFFFAOYSA-N trimethyl-[5-[1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-5-yl]tetrazol-1-yl]stannane Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1C1=CN(C)C2=CC=C(C=3N(N=NN=3)[Sn](C)(C)C)C=C12 PXSQLMPCRDHKPE-UHFFFAOYSA-N 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0115109.1A GB0115109D0 (en) | 2001-06-21 | 2001-06-21 | Chemical compounds |
| US30025701P | 2001-06-22 | 2001-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ20033444A3 true CZ20033444A3 (en) | 2004-03-17 |
Family
ID=9917016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20033444A CZ20033444A3 (en) | 2001-06-21 | 2002-06-20 | Azaindoles |
Country Status (37)
Families Citing this family (235)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02006338A (es) | 1999-12-24 | 2002-12-13 | Aventis Pharma Ltd | Azaindoles. |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| CA2495216A1 (en) | 2002-08-12 | 2004-02-19 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| SE0202463D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| BR0315233A (pt) * | 2002-10-09 | 2005-08-23 | Scios Inc | Derivados de azaindol como inibidores de p38 cinase |
| US20050043212A1 (en) * | 2002-10-09 | 2005-02-24 | Ford Kirschenbaum | Differential inhibition of p38 map kinase isoforms |
| US20050288299A1 (en) * | 2002-10-09 | 2005-12-29 | Mavunkel Babu J | Azaindole derivatives as inhibitors of p38 kinase |
| US7098231B2 (en) * | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| GB0305142D0 (en) * | 2003-03-06 | 2003-04-09 | Eisai London Res Lab Ltd | Synthesis |
| SE0301372D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| US7226941B2 (en) * | 2003-06-30 | 2007-06-05 | Hif Bio, Inc. | Compound for treating angiogenesis |
| US7202363B2 (en) | 2003-07-24 | 2007-04-10 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
| RS53109B (sr) | 2003-07-30 | 2014-06-30 | Rigel Pharmaceuticals Inc. | Jedinjenja 2,4 pirimidindiamina za upotrebu u tretmanu ili prevenciji autoimunih bolesti |
| JP2007513184A (ja) | 2003-12-04 | 2007-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なキノキサリン |
| WO2005061519A1 (en) | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
| SG184700A1 (en) * | 2004-02-20 | 2012-10-30 | Boehringer Ingelheim Int | Viral polymerase inhibitors |
| EP2332940B1 (en) | 2004-03-30 | 2012-10-31 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
| FR2868422B1 (fr) | 2004-03-31 | 2006-07-14 | Aventis Pharma Sa | Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| WO2005097129A2 (en) * | 2004-04-05 | 2005-10-20 | Takeda Pharmaceutical Company Limited | 6-azaindole compound |
| WO2005105788A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
| EP1781654A1 (en) * | 2004-07-27 | 2007-05-09 | SGX Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| BRPI0513982A (pt) * | 2004-07-30 | 2007-11-27 | Methylgene Inc | inibidores de sinalização de receptor de vegf e receptor de hgf |
| MX2007001399A (es) * | 2004-08-02 | 2007-04-18 | Osi Pharm Inc | Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas. |
| US7550598B2 (en) | 2004-08-18 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| WO2006021886A1 (en) * | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
| FR2876103B1 (fr) * | 2004-10-01 | 2008-02-22 | Aventis Pharma Sa | Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| MY179032A (en) * | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| CN101098872B (zh) * | 2004-11-22 | 2012-09-05 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的吡咯并吡嗪和吡唑并吡嗪 |
| JP4954086B2 (ja) * | 2004-12-08 | 2012-06-13 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 1h−ピロロ[2,3−b]ピリジン |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| WO2006066914A2 (en) * | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| ATE524467T1 (de) * | 2005-04-25 | 2011-09-15 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
| FR2884821B1 (fr) | 2005-04-26 | 2007-07-06 | Aventis Pharma Sa | Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation |
| BRPI0610322B8 (pt) | 2005-05-20 | 2021-05-25 | Methylgene Inc | inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica |
| NZ564065A (en) * | 2005-05-20 | 2011-03-31 | Vertex Pharma | Pyrrolopyridines useful as inhibitors of protein kinase |
| US7790729B2 (en) | 2005-05-20 | 2010-09-07 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
| WO2006135915A2 (en) | 2005-06-13 | 2006-12-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
| DE602005000514T2 (de) * | 2005-06-17 | 2007-10-25 | Magneti Marelli Powertrain S.P.A. | Brennstoffeinspritzventil |
| TWI473808B (zh) * | 2005-06-22 | 2015-02-21 | Plexxikon Inc | 用於激酶調節的化合物及方法及其適應症 |
| KR101142363B1 (ko) * | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
| CN102127078A (zh) * | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| CA2618682C (en) * | 2005-08-12 | 2011-06-21 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| WO2007073432A2 (en) | 2005-10-11 | 2007-06-28 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
| US7371862B2 (en) | 2005-11-11 | 2008-05-13 | Pfizer Italia S.R.L. | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| EP1948657A1 (en) * | 2005-11-15 | 2008-07-30 | Vertex Pharmaceuticals Incorporated | Azaindazoles useful as inhibitors of kinases |
| JP2009531274A (ja) * | 2005-12-07 | 2009-09-03 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | キナーゼ阻害性ピロロピリジン化合物 |
| PT1966202E (pt) | 2005-12-13 | 2012-01-03 | Incyte Corp | Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase |
| AU2006333522A1 (en) | 2005-12-21 | 2007-07-12 | Decode Genetics, Ehf. | Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation |
| CN102532134A (zh) | 2006-01-17 | 2012-07-04 | 沃泰克斯药物股份有限公司 | 适用作詹纳斯激酶抑制剂的吖吲哚类 |
| PL2010493T3 (pl) * | 2006-04-12 | 2016-08-31 | Merck Sharp & Dohme | Pirydyloamidy jako antagoniści kanałów wapniowych typu t |
| JP5225264B2 (ja) * | 2006-05-09 | 2013-07-03 | ノベアメド・リミテッド | 細胞増殖障害の処置 |
| JP5682051B2 (ja) * | 2006-05-18 | 2015-03-11 | ファーマサイクリックス,インク. | 細胞内キナーゼ阻害剤 |
| GB0617161D0 (en) * | 2006-08-31 | 2006-10-11 | Vernalis R&D Ltd | Enzyme inhibitors |
| CL2007002617A1 (es) * | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
| EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| EP2124951B1 (en) | 2006-12-21 | 2014-05-21 | Vertex Pharmaceuticals Inc. | 5-cyan0-4- (pyrrolo[2, 3b]pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| PE20121126A1 (es) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| US20090068110A1 (en) * | 2006-12-22 | 2009-03-12 | Genentech, Inc. | Antibodies to insulin-like growth factor receptor |
| ES2422284T3 (es) | 2007-03-29 | 2013-09-10 | Daiichi Sankyo Co Ltd | Derivado de indol que tiene actividad inhibidora de cPLA2, uso del mismo y método para producirlo |
| RS53245B2 (sr) | 2007-06-13 | 2022-10-31 | Incyte Holdings Corp | Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila |
| SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
| JP5524071B2 (ja) | 2007-10-24 | 2014-06-18 | メルク・シャープ・アンド・ドーム・コーポレーション | 複素環フェニルアミドt型カルシウムチャネルアンタゴニスト |
| AU2008317352A1 (en) * | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Heterocycle amide T-type calcium channel antagonists |
| WO2009106441A1 (en) * | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| ATE517107T1 (de) | 2008-02-25 | 2011-08-15 | Hoffmann La Roche | Pyrrolopyrazinkinaseinhibitoren |
| WO2009106444A1 (en) | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| EP2250172B1 (en) | 2008-02-25 | 2011-08-31 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
| RU2503676C2 (ru) | 2008-02-25 | 2014-01-10 | Ф.Хоффманн-Ля Рош Аг | Пирролопиразиновые ингибиторы киназы |
| TW200940549A (en) | 2008-03-05 | 2009-10-01 | Methylgene Inc | Inhibitors of protein tyrosine kinase activity |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| EP2252293B1 (en) | 2008-03-14 | 2018-06-27 | Intellikine, LLC | Kinase inhibitors and methods of use |
| AU2009248923B2 (en) | 2008-05-21 | 2015-01-29 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| CN104530052A (zh) * | 2008-06-10 | 2015-04-22 | 普莱希科公司 | 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症 |
| BRPI0915231A2 (pt) * | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
| US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| JP5590040B2 (ja) | 2008-11-12 | 2014-09-17 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのピラジノピラジンおよび誘導体 |
| ES2524966T3 (es) | 2008-12-05 | 2014-12-16 | Abbvie Bahamas Ltd. | Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer |
| AU2009324210A1 (en) * | 2008-12-05 | 2010-06-10 | F. Hoffmann-La Roche Ag | Pyrrolopyrazinyl urea kinase inhibitors |
| CA2744563A1 (en) * | 2008-12-12 | 2010-06-17 | Ariad Pharmaceuticals, Inc. | Azaindole derivatives as kinase inhibitors |
| MY201120A (en) * | 2009-02-25 | 2024-02-06 | Takeda Pharmaceuticals Co | Intermediates for use in a process of producing pyrrole compounds |
| US20110112101A1 (en) * | 2009-03-05 | 2011-05-12 | Sanofi-Aventis | Treatment for ocular-related disorders |
| AU2010232670B2 (en) | 2009-04-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
| WO2010135411A2 (en) * | 2009-05-19 | 2010-11-25 | The Regents Of The University Of Colorado | Aurora-a copy number and sensitivity to inhibitors |
| WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
| KR101903354B1 (ko) * | 2009-06-17 | 2018-10-04 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| MX2012005284A (es) | 2009-11-06 | 2012-06-28 | Plexxikon Inc | Compuestos y metodos para la modulacion de cinasas. e indicaciones para ello. |
| EP2338890A1 (en) | 2009-12-22 | 2011-06-29 | Bayer CropScience AG | 4,7-Diazaindole derivatives and their use as fungicides |
| US8440689B2 (en) | 2009-12-23 | 2013-05-14 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones |
| MX2012008641A (es) * | 2010-01-27 | 2012-11-23 | Vertex Pharma | Inhibidores de cinasas de pirazolopirazinas. |
| WO2011109932A1 (en) * | 2010-03-09 | 2011-09-15 | F.Hoffmann-La Roche Ag | Novel process for the manufacture of 5-halogenated-7-azaindoles |
| MX354212B (es) | 2010-03-10 | 2018-02-19 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
| US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| US8481541B2 (en) | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| CN103003281A (zh) * | 2010-05-20 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为JAK和SYK抑制剂的吡咯并[2,3-b]吡嗪-7-甲酰胺衍生物和它们的用途 |
| TWI496785B (zh) | 2010-05-20 | 2015-08-21 | Hoffmann La Roche | 吡咯并吡激酶抑制劑 |
| EA202091303A3 (ru) | 2010-05-21 | 2021-05-31 | Инсайт Холдингс Корпорейшн | Композиция ингибитора jak для местного применения |
| CA2800176C (en) * | 2010-05-24 | 2018-08-28 | University Of Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
| WO2011153049A1 (en) | 2010-06-02 | 2011-12-08 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to her2/neu receptor complex |
| WO2011153050A1 (en) | 2010-06-02 | 2011-12-08 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to her2/neu receptor complex |
| AU2011323484B2 (en) * | 2010-11-01 | 2016-10-06 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as Syk modulators |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| EP2651940A1 (en) | 2010-12-16 | 2013-10-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| KR101911972B1 (ko) | 2011-02-07 | 2018-10-25 | 플렉시콘 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| TWI592411B (zh) | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | 激酶抑制劑之組合及其用途 |
| US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| EP2706852B1 (en) | 2011-05-10 | 2018-08-22 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
| MX2013013090A (es) | 2011-05-10 | 2013-12-16 | Merck Sharp & Dohme | Aminopirimidinas como inhibidores de tirosina cinaza del bazo. |
| JP2014513687A (ja) | 2011-05-10 | 2014-06-05 | メルク・シャープ・アンド・ドーム・コーポレーション | Syk阻害薬としてのピリジルアミノピリジン |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| EP2723739B1 (en) | 2011-06-22 | 2016-08-24 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
| JP2014520815A (ja) | 2011-07-05 | 2014-08-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | アザインドールを作製するための方法および中間体 |
| US8436179B2 (en) | 2011-07-20 | 2013-05-07 | Abbvie Inc. | Kinase inhibitor with improved solubility profile |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| DE102011111400A1 (de) | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
| ES2711777T3 (es) | 2011-09-14 | 2019-05-07 | Samumed Llc | Indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de Wnt/b-catenina |
| EP2763976B1 (en) | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| EP2763974B1 (en) | 2011-10-05 | 2016-09-14 | Merck Sharp & Dohme Corp. | Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| WO2013052393A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| CA2869954C (en) | 2012-04-20 | 2023-01-03 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| SI2861595T1 (sl) | 2012-06-13 | 2017-04-26 | Incyte Holdings Corporation | Substituirane triciklične spojine kot inhibitorji fgfr |
| WO2013192128A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
| WO2013192125A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
| EP2863916B1 (en) | 2012-06-22 | 2018-07-18 | Merck Sharp & Dohme Corp. | Substituted pyridine spleen tyrosine kinase (syk) inhibitors |
| US9416111B2 (en) | 2012-06-22 | 2016-08-16 | Merck Sharp & Dohme Corp. | Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors |
| CN102718694B (zh) * | 2012-06-27 | 2014-04-02 | 上海大学 | 3-氰基取代吲哚化合物及其合成方法 |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| WO2014031438A2 (en) | 2012-08-20 | 2014-02-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| NZ708157A (en) | 2012-11-15 | 2019-07-26 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| EP2738172A1 (en) * | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| WO2014110086A2 (en) | 2013-01-08 | 2014-07-17 | Samumed, Llc | 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| TWI634121B (zh) | 2013-03-06 | 2018-09-01 | 英塞特控股公司 | 用於製備jak抑制劑之方法及中間物 |
| WO2014164749A1 (en) | 2013-03-13 | 2014-10-09 | Forma Therapeutics, Inc. | Novel compounds and compositions for inhibition of fasn |
| TW201444836A (zh) * | 2013-03-14 | 2014-12-01 | Abbvie Inc | 吡咯并[2,3-b]吡啶cdk9激酶抑制劑 |
| MX2015012899A (es) | 2013-03-14 | 2016-06-02 | Abbvie Inc | Pirrolo [2,3-b] piridina como inhibidores de quinasa cdk9. |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| LT2986610T (lt) | 2013-04-19 | 2018-04-10 | Incyte Holdings Corporation | Bicikliniai heterociklai, kaip fgfr inhibitoriai |
| MX394928B (es) | 2013-08-07 | 2025-03-24 | Incyte Holdings Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
| JPWO2015029447A1 (ja) * | 2013-08-30 | 2017-03-02 | 興和株式会社 | 光学活性カルビノール化合物の製造方法 |
| ES2684755T3 (es) | 2013-11-13 | 2018-10-04 | Vertex Pharmaceuticals Incorporated | Métodos para preparar inhibidores de la replicación de virus de la gripe |
| DK3068776T3 (da) | 2013-11-13 | 2019-07-29 | Vertex Pharma | Inhibitorer af replikation af influenzavira |
| WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
| WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| KR20170098865A (ko) | 2014-12-11 | 2017-08-30 | 베타 파마, 인크. | Egfr 조정제로서의 치환된 2-아닐리노피리미딘 유도체 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| SG10201913036RA (en) | 2015-02-20 | 2020-02-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| US10287401B2 (en) | 2015-07-01 | 2019-05-14 | California Institute Of Technology | Cationic mucic acid polymer-based delivery systems |
| WO2017023989A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| US10463651B2 (en) | 2015-08-03 | 2019-11-05 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof |
| WO2017023980A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| WO2017023988A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017024026A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| WO2017024025A1 (en) | 2015-08-03 | 2017-02-09 | Sunil Kumar Kc | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017023987A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
| US10604512B2 (en) | 2015-08-03 | 2020-03-31 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof |
| US10329309B2 (en) | 2015-08-03 | 2019-06-25 | Samumed, Llc | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10206909B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| WO2017024003A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017023984A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| WO2017024021A1 (en) * | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| DK3362449T3 (da) * | 2015-10-13 | 2021-07-19 | Inst Nat Sante Rech Med | Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose |
| CN108473491A (zh) | 2015-11-06 | 2018-08-31 | 萨穆梅德有限公司 | 2-(1h-吲唑-3-基)-3h-咪唑并[4,5-c]吡啶以及其抗炎用途 |
| WO2017100201A1 (en) * | 2015-12-07 | 2017-06-15 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| AR107030A1 (es) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores aza-bencimidazol de pad4 |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| PT3464266T (pt) | 2016-06-01 | 2021-11-23 | Bayer Pharma AG | Indazóis substituídos para tratamento e prevenção de doenças alérgicas e/ou inflamatórias em animais |
| MX390577B (es) | 2016-06-01 | 2025-03-20 | Samumed Llc | Proceso de preparación de n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida. |
| CN106008306A (zh) * | 2016-06-28 | 2016-10-12 | 山东大学 | 取代吲哚类衍生物及其制备方法与应用 |
| KR102593742B1 (ko) | 2016-10-21 | 2023-10-24 | 사뮤메드, 엘엘씨 | 인다졸-3-카복사마이드를 사용하는 방법 및 wnt/b-카테닌 신호전달 경로 억제제로서의 그들의 용도 |
| JP7630905B2 (ja) | 2016-11-07 | 2025-02-18 | バイオスプライス セラピューティクス インコーポレイテッド | 単回用量の調整済み注射用製剤 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
| BR112019026483A2 (pt) | 2017-06-16 | 2020-07-14 | Beta Pharma, Inc. | formulação farmacêutica de n-(2-(2-(dimetilamina)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amina)fenil)acrilamida e seus sais |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| WO2019152374A1 (en) | 2018-01-30 | 2019-08-08 | Incyte Corporation | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| HUE067471T2 (hu) | 2018-03-30 | 2024-10-28 | Incyte Corp | Gennyes verejtékmirigy-gyulladás kezelése jak inhibitorok alkalmazásával |
| CN108358894B (zh) * | 2018-04-26 | 2021-05-07 | 四川大学 | 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用 |
| KR20210018264A (ko) | 2018-05-04 | 2021-02-17 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| PL3788047T3 (pl) | 2018-05-04 | 2025-04-14 | Incyte Corporation | Stałe postacie inhibitora fgfr i sposoby ich otrzymywania |
| WO2019241327A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles for crossing the blood brain barrier and methods of treatment using the same |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| TW202039481A (zh) | 2018-12-21 | 2020-11-01 | 美商西建公司 | Ripk2之噻吩并吡啶抑制劑 |
| CN114040760B (zh) | 2018-12-31 | 2025-05-09 | 拜欧米富士恩公司 | Menin-mll相互作用的不可逆抑制剂 |
| WO2020142559A1 (en) | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Inhibitors of menin-mll interaction |
| US12304897B2 (en) | 2019-01-31 | 2025-05-20 | Kyorin Pharmaceutical Co., Ltd. | 15-PGDH inhibitors |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| CN111171001B (zh) * | 2019-05-16 | 2022-04-29 | 百济神州(苏州)生物科技有限公司 | 一种parp抑制剂中间体的结晶方法 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CR20220169A (es) | 2019-10-14 | 2022-10-27 | Incyte Corp | Heterociclos bicíclicos como inhibidores de fgfr |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3161049A1 (en) * | 2020-01-30 | 2021-08-05 | David William Sheppard | Collagen 1 translation inhibitors and methods of use thereof |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含fgfr抑制劑及nectin-4靶向劑之組合療法 |
| EP4352060A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| US12251385B2 (en) | 2021-08-11 | 2025-03-18 | Biomea Fusion, Inc. | Covalent inhibitors of menin-MLL interaction for diabetes mellitus |
| WO2023022912A1 (en) | 2021-08-20 | 2023-02-23 | Biomea Fusion, Inc. | Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer |
| EP4561567A2 (en) * | 2022-07-28 | 2025-06-04 | University of Maryland, Baltimore | Inhibitors of pde11a4 and methods of using same |
| WO2024155719A1 (en) | 2023-01-18 | 2024-07-25 | Biomea Fusion, Inc. | Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB966264A (en) | 1961-08-31 | 1964-08-06 | Distillers Co Yeast Ltd | Production of alkyl pyridines |
| GB1141949A (en) | 1966-02-23 | 1969-02-05 | Sterling Drug Inc | 7-azaindole derivatives |
| US3992392A (en) | 1973-04-27 | 1976-11-16 | The Ohio State University Research Foundation | Synthesis of indoles from anilines and intermediates therein |
| EP0405602A1 (en) | 1989-06-30 | 1991-01-02 | Laboratorios Vinas S.A. | New Zinc derivatives of anti-inflammatory drugs having improved therapeutic activity |
| SE9100920D0 (sv) | 1991-03-27 | 1991-03-27 | Astra Ab | New active compounds |
| FR2687402B1 (fr) | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
| JP3119758B2 (ja) | 1993-02-24 | 2000-12-25 | 日清製粉株式会社 | 7−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬 |
| US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| DE4435477A1 (de) * | 1994-10-04 | 1996-04-11 | Bayer Ag | Cycloalkano-indol- und -azaindol-derivate |
| US5589482A (en) | 1994-12-14 | 1996-12-31 | Pfizer Inc. | Benzo-thiophene estrogen agonists to treat prostatic hyperplasia |
| GB2298199A (en) | 1995-02-21 | 1996-08-28 | Merck Sharp & Dohme | Synthesis of azaindoles |
| FR2732969B1 (fr) | 1995-04-14 | 1997-05-16 | Adir | Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| DE59704157D1 (de) | 1996-01-30 | 2001-09-06 | Ciba Sc Holding Ag | Polymerisierbare Diketopyrrolopyrrole und damit hergestellte Polymere |
| WO1998002437A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| JP2000516611A (ja) | 1996-08-14 | 2000-12-12 | ワーナー―ランバート・コンパニー | Mcp―1アンタゴニストとしての2―フェニルベンズイミダゾール誘導体 |
| HUP9903330A2 (hu) | 1996-11-19 | 2000-03-28 | Amgen Inc. | Gyulladásgátló hatású, aril- és heteroaril csoporttal szubsztituált kondenzált pirrolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények |
| US6312835B1 (en) | 1997-02-13 | 2001-11-06 | Queen's University At Kingston | Luminescent compounds and methods of making and using same |
| AU7132998A (en) * | 1997-04-24 | 1998-11-13 | Ortho-Mcneil Corporation, Inc. | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases |
| EP1025102B1 (en) * | 1997-10-20 | 2004-05-19 | F. Hoffmann-La Roche Ag | Bicyclic kinase inhibitors |
| JP4741725B2 (ja) | 1998-03-06 | 2011-08-10 | メタベイシス・セラピューティクス・インコーポレーテッド | リン含有化合物のための新規なプロドラッグ |
| JP2002510628A (ja) | 1998-04-02 | 2002-04-09 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬 |
| AU3210899A (en) | 1998-04-02 | 1999-10-25 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6025366A (en) | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| EP1071423A1 (en) | 1998-04-02 | 2001-01-31 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| WO1999051596A1 (en) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| AU3118399A (en) | 1998-04-02 | 1999-10-25 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| AU3210799A (en) | 1998-04-02 | 1999-10-25 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| ATE229015T1 (de) | 1998-05-12 | 2002-12-15 | Wyeth Corp | Zur behandlung von insulin-resistenz und hyperglycemie geeignete biphenyl-oxo-essigsäuren |
| US6673797B1 (en) * | 1998-05-26 | 2004-01-06 | Chugai Seiyaku Kabushiki Kaisha | Heterocyclic indole derivatives and mono- or diazaindole derivatives |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| SE510289C2 (sv) | 1998-06-09 | 1999-05-10 | Car O Liner Ab | Fastspänningsanordning för fordon vid en riktbänk |
| DE69928414T2 (de) * | 1998-09-18 | 2006-08-03 | Abbott Gmbh & Co. Kg | 4-aminopyrrolopyrimidine als kinaseinhibitoren |
| ES2228154T3 (es) | 1998-12-31 | 2005-04-01 | Aventis Pharmaceuticals Inc. | Alfa-sustitucion de compuestos beta-amino-esteres desprotegidos. |
| EP1189889B1 (en) | 1999-06-04 | 2003-12-17 | Elan Pharma International Limited | Compositions and methods for inhibiting cell death |
| US6207699B1 (en) | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| DE19951360A1 (de) | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
| MXPA02006338A (es) * | 1999-12-24 | 2002-12-13 | Aventis Pharma Ltd | Azaindoles. |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| CA2400447C (en) | 2000-02-17 | 2008-04-22 | Amgen Inc. | Kinase inhibitors |
| DE10009000A1 (de) | 2000-02-25 | 2001-08-30 | Basf Ag | Verfahren zur Herstellung substituierter Indole |
| EP1259236A4 (en) | 2000-02-25 | 2004-11-03 | Merck & Co Inc | Tyrosine kinase inhibitors |
| GB0007657D0 (en) | 2000-03-29 | 2000-05-17 | Celltech Therapeutics Ltd | Chemical compounds |
| CA2398446A1 (en) | 2000-04-18 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinases |
| US6943174B2 (en) * | 2000-06-14 | 2005-09-13 | Warner-Lambert Company | 6,5-Fused bicyclic heterocycles |
| US6407259B1 (en) | 2000-07-28 | 2002-06-18 | Pfizer Inc. | Process for the preparation of pyrazoles |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| JP2004510762A (ja) | 2000-10-02 | 2004-04-08 | メルク エンド カムパニー インコーポレーテッド | プレニル−蛋白質トランスフェラーゼの阻害剤 |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
-
2001
- 2001-06-21 GB GBGB0115109.1A patent/GB0115109D0/en not_active Ceased
-
2002
- 2002-06-20 RU RU2004101408/04A patent/RU2326880C2/ru not_active IP Right Cessation
- 2002-06-20 CN CNB028124766A patent/CN100509811C/zh not_active Expired - Fee Related
- 2002-06-20 KR KR1020097006249A patent/KR100977344B1/ko not_active Expired - Fee Related
- 2002-06-20 IL IL15944502A patent/IL159445A0/xx unknown
- 2002-06-20 SI SI200220015A patent/SI21462A/sl not_active IP Right Cessation
- 2002-06-20 EP EP02730531A patent/EP1397360A1/en not_active Withdrawn
- 2002-06-20 KR KR1020037016763A patent/KR100915289B1/ko not_active Expired - Fee Related
- 2002-06-20 JP JP2003507091A patent/JP4409938B2/ja not_active Expired - Fee Related
- 2002-06-20 PL PL02365067A patent/PL365067A1/xx not_active Application Discontinuation
- 2002-06-20 CA CA2451678A patent/CA2451678C/en not_active Expired - Fee Related
- 2002-06-20 EE EEP200400015A patent/EE200400015A/xx unknown
- 2002-06-20 SK SK1590-2003A patent/SK15902003A3/sk not_active Application Discontinuation
- 2002-06-20 HU HU0400247A patent/HUP0400247A2/hu unknown
- 2002-06-20 JO JO200264A patent/JO2327B1/en active
- 2002-06-20 TW TW091113956A patent/TWI334417B/zh not_active IP Right Cessation
- 2002-06-20 BR BR0210507-1A patent/BR0210507A/pt not_active IP Right Cessation
- 2002-06-20 WO PCT/GB2002/002799 patent/WO2003000688A1/en not_active Ceased
- 2002-06-20 OA OA1200300343A patent/OA12637A/en unknown
- 2002-06-20 AP APAP/P/2003/002940A patent/AP1739A/en active
- 2002-06-20 NZ NZ545741A patent/NZ545741A/en unknown
- 2002-06-20 EP EP09171579A patent/EP2233486A1/en not_active Withdrawn
- 2002-06-20 CZ CZ20033444A patent/CZ20033444A3/cs unknown
- 2002-06-20 NZ NZ529205A patent/NZ529205A/en unknown
- 2002-06-20 YU YU96903A patent/YU96903A/sh unknown
- 2002-06-20 HR HR20031069A patent/HRP20031069A2/hr not_active Application Discontinuation
- 2002-06-20 UA UA2004010424A patent/UA85660C2/ru unknown
- 2002-06-21 HN HN2002000154A patent/HN2002000154A/es unknown
- 2002-06-21 US US10/177,804 patent/US6897207B2/en not_active Expired - Fee Related
- 2002-06-21 PE PE2002000541A patent/PE20030155A1/es not_active Application Discontinuation
- 2002-06-21 MY MYPI20022345A patent/MY137099A/en unknown
- 2002-06-21 AR ARP020102348A patent/AR036106A1/es unknown
- 2002-06-21 PA PA20028548701A patent/PA8548701A1/es unknown
- 2002-06-21 UY UY27350A patent/UY27350A1/es unknown
-
2003
- 2003-07-08 TN TNPCT/GB2002/002799A patent/TNSN03110A1/en unknown
- 2003-12-09 NO NO20035476A patent/NO20035476D0/no unknown
- 2003-12-11 ZA ZA200309468A patent/ZA200309648B/xx unknown
- 2003-12-18 EC EC2003004914A patent/ECSP034914A/es unknown
- 2003-12-19 BG BG108481A patent/BG108481A/bg unknown
- 2003-12-19 MA MA27453A patent/MA27043A1/fr unknown
-
2004
- 2004-11-23 US US10/995,103 patent/US7943616B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100977344B1 (ko) | 아자인돌 | |
| KR100910488B1 (ko) | 아자인돌 | |
| JP4871474B2 (ja) | アザインドール | |
| AU2002302849A1 (en) | Azaindoles | |
| AU2009200024A1 (en) | Azaindoles |